
<html lang="en"     class="pb-page"  data-request-id="602e2323-bc4f-4a72-839d-f6e4b21c0224"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2011.54.issue-7;article:article:10.1021/jm100972f;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Pro-Soft Val-boroPro: A Strategy for Enhancing in Vivo Performance of Boronic Acid Inhibitors of Serine Proteases" /></meta><meta name="dc.Creator" content="Sarah E.  Poplawski" /></meta><meta name="dc.Creator" content="Jack H.  Lai" /></meta><meta name="dc.Creator" content="David G.  Sanford" /></meta><meta name="dc.Creator" content="James L.  Sudmeier, Wengen Wu" /></meta><meta name="dc.Creator" content="William W.  Bachovchin" /></meta><meta name="dc.Description" content="Val-boroPro, 1, is a potent, but relatively nonspecific inhibitor of the prolyl peptidases. It has antihyperglycemic activity from inhibition of DPPIV but also striking anticancer activity and a to..." /></meta><meta name="Description" content="Val-boroPro, 1, is a potent, but relatively nonspecific inhibitor of the prolyl peptidases. It has antihyperglycemic activity from inhibition of DPPIV but also striking anticancer activity and a to..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 9, 2011" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm100972f" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2011 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm100972f" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm100972f" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm100972f" /></link>
        
    
    

<title>Pro-Soft Val-boroPro: A Strategy for Enhancing in Vivo Performance of Boronic Acid Inhibitors of Serine Proteases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm100972f" /></meta><meta property="og:title" content="Pro-Soft Val-boroPro: A Strategy for Enhancing in Vivo Performance of Boronic Acid Inhibitors of Serine Proteases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0013.jpeg" /></meta><meta property="og:description" content="Val-boroPro, 1, is a potent, but relatively nonspecific inhibitor of the prolyl peptidases. It has antihyperglycemic activity from inhibition of DPPIV but also striking anticancer activity and a toxicity for which the mechanisms are unknown. 1 cyclizes at physiological pH, which attenuates its inhibitory potency &gt;100-fold, which is a “soft drug” effect. Here we show that this phenomenon can be exploited to create prodrugs with unique properties and potential for selective in vivo targeting. Enzyme-mediated release delivers 1 to the target in the active form at physiological pH; cyclization attenuates systemic pharmacological effects from subsequent diffusion. This “pro-soft” design is demonstrated with a construct activated by and targeted to DPPIV, including in vivo results showing improved antihyperglycemic activity and reduced toxicity relative to 1. Pro-soft derivatives of 1 can help to illuminate the mechanisms underlying the three biological activities, or to help localize 1 at a tumor and thereby lead to improved anticancer agents with reduced toxicity. The design concept can also be applied to a variety of other boronic acid inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm100972f"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm100972f">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm100972f&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm100972f&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm100972f&amp;href=/doi/10.1021/jm100972f" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2011</span><span class="cit-fg-volume">, 54</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 2022-2028</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/54/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm1009428" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm101023r" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Pro-Soft Val-boroPro: A Strategy for Enhancing in Vivo Performance of Boronic Acid Inhibitors of Serine Proteases</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+E.++Poplawski">Sarah E. Poplawski</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jack+H.++Lai">Jack H. Lai</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+G.++Sanford">David G. Sanford</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+L.++Sudmeier%2C+Wengen+Wu">James L. Sudmeier, Wengen Wu</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+W.++Bachovchin">William W. Bachovchin</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Tufts University Sackler School of Graduate Biomedical Sciences, Department of Biochemistry, 136 Harrison Avenue, Boston, Massachusetts 02111, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 617-636-6881. Fax: 617-696-2409. E-mail: <a href="/cdn-cgi/l/email-protection#addac4c1c1c4ccc083cfcccec5c2dbcec5c4c3edd9d8cbd9de83c8c9d8"><span class="__cf_email__" data-cfemail="3f48565353565e52115d5e5c5750495c5756517f4b4a594b4c115a5b4a">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm100972f&amp;href=/doi/10.1021%2Fjm100972f" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2011</span></span><span class="cit-volume">, 54</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 2022–2028</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 9, 2011</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 July 2010</li><li><span class="item_label"><b>Published</b> online</span>9 March 2011</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 April 2011</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm100972f" title="DOI URL">https://doi.org/10.1021/jm100972f</a></div><div class="article_header-article-copyright"><strong>Copyright © 2011 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2022%26pageCount%3D7%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSarah%2BE.%2BPoplawski%252C%2BJack%2BH.%2BLai%252C%2BDavid%2BG.%2BSanford%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D54%26issueNum%3D7%26contentID%3Djm100972f%26title%3DPro-Soft%2BVal-boroPro%253A%2BA%2BStrategy%2Bfor%2BEnhancing%2Bin%2BVivo%2BPerformance%2Bof%2BBoronic%2BAcid%2BInhibitors%2Bof%2BSerine%2BProteases%26numPages%3D7%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2028%26publicationDate%3DApril%2B2011">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm100972f"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1563</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">16</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm100972f" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Pro-Soft Val-boroPro: A Strategy for Enhancing in Vivo Performance of Boronic Acid Inhibitors of Serine Proteases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;E. Poplawski&quot;},{&quot;first_name&quot;:&quot;Jack&quot;,&quot;last_name&quot;:&quot;H. Lai&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;G. Sanford&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;L. Sudmeier, Wengen Wu&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;W. Bachovchin&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2011&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;54&quot;,&quot;pages&quot;:&quot;2022-2028&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm100972f&quot;},&quot;abstract&quot;:&quot;Val-boroPro, 1, is a potent, but relatively nonspecific inhibitor of the prolyl peptidases. It has antihyperglycemic activity from inhibition of DPPIV but also striking anticancer activity and a toxicity for which the mechanisms are unknown. 1 cyclizes at physiological pH, which attenuates its inhibitory potency &gt;100-fold, which is a “soft drug” effect. Here we show that this phenomenon can be exploited to create prodrugs with unique properties and potential for selective in vivo targeting. Enzyme-mediated release delivers 1 to the target in the active form at physiological pH; cyclization attenuates systemic pharmacological effects from subsequent diffusion. This “pro-soft” design is demonstrated with a construct activated by and targeted to DPPIV, including in vivo results showing improved antihyperglycemic activity and reduced toxicity relative to 1. Pro-soft derivatives of 1 can help to illuminate the mechanisms underlying the three biological activities, or to help localize 1 at a tumor and thereby lead &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100972f&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100972f" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100972f&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100972f" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100972f&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100972f" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm100972f&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100972f&amp;href=/doi/10.1021/jm100972f" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm100972f" /></input><a href="/doi/pdf/10.1021/jm100972f" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm100972f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm100972f%26sid%3Dliteratum%253Aachs%26pmid%3D21388136%26genre%3Darticle%26aulast%3DPoplawski%26date%3D2011%26atitle%3DPro-Soft%2BVal-boroPro%253A%2BA%2BStrategy%2Bfor%2BEnhancing%2Bin%2BVivo%2BPerformance%2Bof%2BBoronic%2BAcid%2BInhibitors%2Bof%2BSerine%2BProteases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D54%26issue%3D7%26spage%3D2022%26epage%3D2028%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/54/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jmcmar.2011.54.issue-7/production/jmcmar.2011.54.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Val-boroPro, <b>1</b>, is a potent, but relatively nonspecific inhibitor of the prolyl peptidases. It has antihyperglycemic activity from inhibition of DPPIV but also striking anticancer activity and a toxicity for which the mechanisms are unknown. <b>1</b> cyclizes at physiological pH, which attenuates its inhibitory potency >100-fold, which is a “soft drug” effect. Here we show that this phenomenon can be exploited to create prodrugs with unique properties and potential for selective in vivo targeting. Enzyme-mediated release delivers <b>1</b> to the target in the active form at physiological pH; cyclization attenuates systemic pharmacological effects from subsequent diffusion. This “pro-soft” design is demonstrated with a construct activated by and targeted to DPPIV, including in vivo results showing improved antihyperglycemic activity and reduced toxicity relative to <b>1</b>. Pro-soft derivatives of <b>1</b> can help to illuminate the mechanisms underlying the three biological activities, or to help localize <b>1</b> at a tumor and thereby lead to improved anticancer agents with reduced toxicity. The design concept can also be applied to a variety of other boronic acid inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83286" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83286" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Val-boroPro, (<b>1</b>), also known as PT-100<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> or talabostat, and closely related dipeptide boronic acids such as Ala-boroPro (<b>2</b>), were first synthesized as inhibitors of dipeptidyl peptidase IV (DPPIV, EC 3.14.5) and were among the first compounds used to interrogate the biological function of DPPIV in vivo and ex vivo.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Since then, DPPIV has been shown to play a key role in regulating the incretin hormones GLP-1 and GIP and has become a validated target for the treatment of type 2 diabetes.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> Two DPPIV inhibitors, sitagliptin and saxagliptin, have been approved to date by the FDA, vildagliptin has been approved in Europe, and several others are in late stage clinical trials.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10">(6-10)</a></div><div class="NLM_p"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0002.gif" alt="" id="fx1" /></img></div><div class="NLM_p">Although <b>1</b> is a potent inhibitor of DPPIV (<i>K</i><sub>i</sub> = 0.18 nM) and exceptionally effective and long-acting in vivo, it was never considered as a clinical candidate for diabetes because it is also quite toxic, especially in Sprague−Dawley rats, where the maximum tolerated dose (MTD) is 0.025 mg/kg.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> However, early on, <b>1</b> was discovered to also have striking anticancer activity in a variety of animal models, even receiving FDA fast track status, but failed to meet its end points in a phase 3 trial of nonsmall cell lung carcinoma for reasons still unclear.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12-14)</a></div><div class="NLM_p">The toxicity of <b>1</b> may have played a role, as the late-stage cancer patients in the trial could not tolerate more than 800 μg/patient/day, a dose that might have been too low for the anticancer effects.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Another possibility, suggested by recent work of Fry and co-workers,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> is that <b>1</b> works well against <i>early</i> stage tumors but not <i>established</i> tumors. These findings might have rendered <b>1</b> of limited interest and value as a cancer drug except that the same group also found <b>1</b> to be quite effective in shrinking <i>established</i> tumors when combined with a dendritic cell vaccine.</div><div class="NLM_p">In either case, the anticancer activity of <b>1</b> remains of interest but would be of considerably greater interest if it could be separated from the toxicity. A knowledge of the mechanisms would be helpful in assessing whether or not and how this might be achieved, but unfortunately, neither mechanism is well understood. The anticancer activity of <b>1</b> appears to be mediated through an immune stimulatory mechanism, but neither the target triggering this activity nor that of the toxicity are known.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> One certainty is that neither activity is mediated solely through the inhibition of DPPIV, as there are a number of highly potent and selective DPPIV inhibitors that lack both toxicity and anticancer activity.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> Another is that <b>1</b> is a relatively nonspecific inhibitor of serine hydrolyses that cleave after proline, inhibiting other members of this group, which include FAP, DPPII, DPP8, DPP9 (usually referred to jointly as DPP8/9 owing to the difficulty in distinguishing between them), and PREP as potently as DPPIV.<a onclick="showRef(event, 'ref11 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref11 ref18 ref19">(11, 18, 19)</a> These other prolyl peptidases should therefore be considered among the most probable targets for both the anticancer activity and toxicity. FAP inhibition has been reported to yield anticancer effects, but the effects are modest and thus cannot alone account for the profound anticancer activity of <b>1</b>.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> Inhibition of DPP8/9 has been implicated in both the anticancer activity<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and toxicity<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> of <b>1</b>. However, their role in these activities is doubtful, as DPP8/9-specific inhibitors exist but have not been reported to trigger immune responses or to demonstrate anticancer activity in vivo, while several groups have challenged the hypothesis that DPP8/9 inhibition causes toxicities.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a></div><div class="NLM_p">Compound <b>1</b> has some unique chemical properties that could be utilized to separate the anticancer activity from the toxicity and to shed light upon the underlying mechanisms. In aqueous solution, <b>1</b> undergoes a reversible, pH-dependent equilibration (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) between an open chain, enzyme−inhibitory form (<b>A</b>) and a cyclic, inactive form (<b>B</b>). The open chain structure predominates at low pH, but as the pH is raised and the N-terminal amino group deprotonates, the cyclic structure becomes increasingly favored.<a onclick="showRef(event, 'ref3 ref24'); return false;" href="javascript:void(0);" class="ref ref3 ref24">(3, 24)</a> A localized, unshared electron pair on the P2 amino nitrogen is required for cyclization, as N-terminally alkylated derivatives such as <i>N</i>-methyl-Val-boroPro will cyclize, but N-terminally acylated derivatives, such as Ac-Val-boroPro or X<sub>aa</sub>-Val-boroPro tripeptides, will not. The cyclization reaction is relatively slow for what is essentially a conformational change (<i>T</i><sub>1/2</sub> ∼ 30 min at physiological pH) but consistent with a prolyl peptide bond isomerization.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Cyclization Equilibrium of Val-boroPro</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">At physiological pH, the equilibrium favors the cyclic over the open chain form by more than 2 orders of magnitude.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> This reduces the pharmacological activity of <b>1</b> by a factor approaching this amount under equilibrium conditions which would likely obtain following systemic administration. The loss in pharmacological activity with time is characteristic of the action of “soft drugs,” drugs designed to deactivate in a predictable and controlled manner to prevent unwanted systemic effects after exerting their therapeutic effects.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a><b>1</b> could therefore be deployed as a soft drug. To do so beneficially would require that it be applied directly to the site of intended action, the modus operandi for all soft drugs. Such application is often difficult, and <b>1</b> presents an additional problem: it would need to be applied in a low (≤2) pH preparation to ensure sufficient excess of the open chain species and the low pH could cause unwanted effects.</div><div class="NLM_p">However, having a free amino group, <b>1</b> is also amenable to incorporation into the C-terminus of a longer peptide or other entity, from where it could be released by the action of a selected protease. Such release would deliver <b>1</b> to the site of the activating protease in the open-chain form with a conformational purity unmatchable by the most sedulous deployment of <b>1</b> directly to the site. The effectiveness of the delivery will, of course, depend on the degree to which the activating protease is localized at the site and the specificity with which the construct is activated by the intended protease. The slow rate of cyclization following release should then allow for a substantial pharmacological effect at the site of release while attenuating effects at more distant sites.</div><div class="NLM_p">Prodrugs of soft drugs have previously been termed “pro-soft” drugs. Although the pro-soft concept has been discussed previously, there are few working examples and there has been little exploration of their potential.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a><b>1</b> is well suited for testing such potential (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). With three distinct biological activities and six known targets, a wide variety of pro-soft constructs of <b>1</b> can be envisaged. Constructs designed to deliver and localize <b>1</b> at targets thought to mediate toxicity or anticancer activity could help to illuminate the underlying mechanisms. Constructs designed to deliver and localize <b>1</b> at a tumor could be a way to obtain the full anticancer activity while reducing toxicity, even if the mechanisms underlying toxicity and the anticancer effects are the same.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Mechanism of pro-soft inhibition of DPPIV. Once the systemically inactive pro-soft drug encounters the DPPIV target enzyme, the N-terminal dipeptide is cleaved, releasing the linear dipeptide inhibitor in close proximity to its target enzyme. Any inhibitor that diffuses away, however, undergoes a pH-dependent cyclization, thereby attenuating potential systemic activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Here we report the in vitro and in vivo characterization of <b>3</b> (Chg-Pro-Val-boroPro), a prodrug of <b>1</b>, which is activated by and targeted to DPPIV. This construct was chosen because it should permit convenient and expeditious evaluation of the performance of the pro-soft design in vivo. DPPIV is an established target for the treatment of type 2 diabetes. Inhibition of DPPIV will have antidiabetic activity, a far easier action to measure than anticancer activity. Furthermore, DPPIV inhibition is clearly not responsible for the toxicity of <b>1</b>. Thus, a DPPIV-activated construct of <b>1</b>, by working to direct <b>1</b> toward DPPIV and away from other potential toxicity-inducing targets, should have a better therapeutic index with respect to blood glucose lowering than <b>1</b>. The results demonstrate that <b>3</b> does indeed have the pro-soft properties outlined above in vitro and in vivo appears to be both safer and more effective as an antihyperglycemic agent than <b>1</b>. The significance of these results and their implications for other pro-soft agents based upon <b>1</b> and other boronic acid inhibitors targeting other enzymes are discussed.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65117" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65117" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Effects of Cyclization on Enzyme Inhibition in Vitro</h3><div class="NLM_p">The inhibitory potency of <b>1</b> depends on the pH of pre-equilibration prior to addition to standard enzyme inhibition assays buffered at pH 7.4. The dipeptide boronic acid inhibitors, <b>1</b> and <b>2</b>, and their corresponding prodrugs, <b>3</b> and <b>4</b> (Sch <a class="ref internalNav" href="#sch2" aria-label="2">2</a>), were preincubated at either pH 2.0 or pH 7.4 and assayed for DPPIV inhibition in vitro. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, <b>1</b> pre-equilibrated at pH 2.0 yields an IC<sub>50</sub> value ∼300-fold lower than when pre-equilibrated at pH 7.4. The effect is fully reversible; adjusting the pH 7.4 pre-equilibration solution to pH 2.0, and incubating for several hours regenerates the inhibitor potency.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Pro-Soft Drugs Chg-Pro-Val-boroPro (<b>3</b>) and Phe-Pro-Ala-boroPro (<b>4</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. pH independence of smarter protease inhibitors in vitro. (A) Dipeptide boronic acid inhibitor <b>1</b> (circles) and its corresponding pro-soft drug <b>3</b> (squares). Open for pH 7.4 and closed for pH 2.0. (B) Dipeptide boronic acid inhibitor <b>2</b> (circles) and its corresponding pro-soft drug <b>4</b> (squares). Open for pH 7.4 and closed for pH 2.0.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values for Dipeptide Boronic Acid Inhibitors <b>1</b> and <b>2</b> and Corresponding Pro-Soft Drugs <b>3</b> and <b>4</b> at Various Pre-equilibrium pH Values</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM) pH 2.0</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM) pH 7.4</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">470</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">1600</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">8.3</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td></tr></tbody></table></div></div><div class="NLM_p last">The difference in IC<sub>50</sub> values between pH 2.0 and 7.4 solutions reflects the different position of the cyclization equilibrium at the two pH values. That this difference can be so readily observed in conventional enzyme assays demonstrates the slowness of the cyclization reaction. It also provides a convenient method for measuring the position of the equilibrium. The closely related inhibitor, <b>2</b>, exhibits the same phenomenon but with a greater difference in IC<sub>50</sub> values (∼1600-fold) indicating that its cyclic form is even more favored at pH 7.4 than it is for <b>1</b>.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Pro-Soft Drug Activation by DPPIV in Vitro</h3><div class="NLM_p">The design strategy outlined above together with known cyclization rates predict that inhibition mediated by prodrugs releasing <b>1</b> or <b>2</b> should appear to be pH-independent in standard inhibition assays. Inhibition kinetics of <b>3</b> and <b>4</b> confirm that this is indeed the case (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Pre-equilibration of <b>3</b> and <b>4</b> at pH 2.0 or pH 7.4 has no effect on the “observed IC<sub>50</sub>” values, in striking contrast to what is observed with the corresponding dipeptide inhibitors themselves. The pH independence cannot be attributed to <b>3</b> and <b>4</b> themselves mediating the inhibition. Peptides of boroPro larger than dipeptides, such as <b>3</b> and <b>4</b>, are not DPPIV inhibitors because they do not contain the requisite free amino group at P2. The inhibition observed for <b>3</b> and <b>4</b> is due entirely to released <b>1</b> and <b>2</b>, respectively.</div><div class="NLM_p last">The pH independent inhibition confirms that the inhibitors are released in the same configuration regardless of pre-equilibration pH, as expected. Moreover, that the IC<sub>50</sub> values of <b>3</b> and <b>4</b> are more similar to those of <b>1</b> and <b>2</b> pre-equilibrated at pH 2.0 than at 7.4 fits with the expectation that the inhibitors would be released in the open-chain and enzyme−inhibitory configuration, even at pH 7.4. The observation that the apparent IC<sub>50</sub> values for the prodrugs are slightly higher than for the corresponding free dipeptide inhibitors preincubated at pH 2.0 can be ascribed largely to the kinetics of activation, not to cyclization. Activation is not instantaneous, and the rate of release slows down as DPPIV becomes inhibited. Both factors will work to attenuate the observed “tetrapeptide IC<sub>50</sub>s” relative to that of the corresponding dipeptide inhibitors added directly.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Soft-Drug Action Following Activation</h3><div class="NLM_p">Demonstrating soft drug action from postactivation cyclization is problematic in a homogeneous system when the activating enzyme and target enzyme are the same, as is case for the DPPIV-mediated activation of <b>3</b> and <b>4</b>, because in this case there is no spatial or temporal separation between activation and inhibition in which cyclization can take place and be measured. <b>5</b> (Suc-Ala-Ala-Pro-Phe-Ala-boroPro) was therefore designed and synthesized to enable the separation needed to demonstrate the soft drug action. <b>5</b> does not itself inhibit DPPIV, nor can it be activated by DPPIV to release the DPPIV inhibitor, <b>2</b>. It also does not inhibit chymotrypsin, but it can be cleaved by chymotrypsin after the phenylalanine residue to release <b>2.</b> Monitoring the loss of DPPIV inhibitory potency of a solution containing <b>5</b> as a function of time following activation by chymotrypsin should provide a demonstration, and measurement, of the soft drug action.</div><div class="NLM_p"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0007.gif" alt="" id="fx2" /></img></div><div class="NLM_p">Compound <b>5</b> was allowed to preincubate with chymotrypsin for varying lengths of time prior to the addition of DPPIV and measurement of DPPIV inhibitory activity. Prior to the addition of chymotrypsin, the solution containing <b>5</b> had little DPPIV inhibitory activity. Immediately following the addition of chymotrypsin, the solution becomes very potently DPPIV inhibitory, yielding an IC<sub>50</sub> value of 0.7 nM with respect to the amount of <b>5</b> contained in the solution. The DPPIV potency of the solution then decreases with time, as expected for cyclization of the DPPIV inhibitor, <b>2</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). This experiment nicely demonstrates the workings of a pro-soft construct in its entirety, from the initial pharmacological inactivity prior to activation, through the hyper-potent phase immediately following activation, to the loss of inhibitory potency with longer postactivation times.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0008.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Time course of pH dependent inactivation of a dipeptide boronic acid inhibitor following prodrug activation. IC<sub>50</sub> values for compound <b>5</b> were measured in vitro in the absence of chymotrypsin or following preincubation with chymotrypsin for varying periods of time.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Direct Evidence for DPPIV-Mediated Activation in Vitro and DPPIV Selectivity in Vivo</h3><div class="NLM_p">The release of <b>1</b> is difficult to directly monitor and measure in vitro and especially in vivo using mass spectrometry for several reasons, including cyclization, high affinity enzyme binding, and the properties of the major ion. In contrast, Chg-Pro, the other product of DPPIV activation, or the intact prodrug itself, <b>3</b>, are relatively easy to directly observe and monitor using mass spectrometry. Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> shows that Chg-Pro is rapidly formed from <b>3</b> following incubation with, but not without, DPPIV in vitro, providing direct evidence for the DPPIV-mediated activation of <b>3</b>.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0009.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pro-soft drug cleavage in vitro, monitoring for the dipeptide metabolite Chg-Pro. Activation of the pro-soft drug, <b>3</b>, in the presence (B), or absence (C) of purified DPPIV. Purified Chg-Pro was run as a reference (A).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although the above experiment shows that DPPIV is capable of activating <b>3</b>, it does not address whether or not other enzymes might also be able to activate this prodrug, a key factor that will affect its performance in vivo. To address this issue, the concentration of <b>3</b> was determined in the serum of DPPIV (CD26) wild-type and knockout mice following intraperitoneal injection (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Significantly larger amounts of <b>3</b> were detected in the serum of knockout mice than in wild-type mice, providing not only direct evidence for DPPIV-mediated activation but also some measure of DPPIV selectively in vivo.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0010.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Cleavage of <b>3</b> in wild-type (CD26<sup>+/+</sup>) and DPPIV knockout (CD26<sup>−/−</sup>) mice. Levels of intact <b>3</b> in serum from wild-type and DPPIV knockout mice previously given an intraperitoneal injection of the molecule were monitored via LC/MS (<i>n</i> = 3). The compound was administered 5 min prior to serum collection. *, <i>P</i> < 0.05. Error bars show mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> In Vivo Performance</h3><div class="NLM_p">To evaluate the in vivo performance of <b>3</b>, its ability to inhibit serum DPPIV activity and to lower the area under the curve (AUC) in an oral glucose tolerance test (OGTT) was compared to that of <b>1</b> at four different orally administered doses in db/db mice. The doses of <b>3</b> are given in mg/kg of contained <b>1</b> so as to be directly comparable. While both compounds were quite effective at inhibiting serum DPPIV and both exhibited dose-dependent inhibition over the range examined, <b>3</b> was the more effective at every dose and time point tested (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A). Furthermore, <b>3</b> was able to bring about a significant lowering of the AUC following a glucose challenge at 0.05 mg/kg,  a dose at which <b>1</b> exhibited little or no effect (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B). Thus, the prodrug of <b>1</b>, <b>3</b>, produces more effective <b>1</b>-mediated inhibition of DPPIV in vivo and more effective antihyperglycemic activity than <b>1</b> itself. A 3-fold higher dose of <b>1</b> would be required to produce an equivalent effect on the OGTT.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0011.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparison of the in vivo performance of a dipeptide inhibitor (compound <b>1</b>) vs a pro-soft drug (compound <b>3</b>) in db/db mice. Serum DPPIV activity both 4 and 7 h following oral administration of 0.0025, 0.01, 0.025, or 0.05 mg/kg of <b>1</b> or <b>3</b> (<i>n</i> = 2, except for 0.5 mg/kg <b>1</b>, where <i>n</i> = 1) (A). Blood glucose levels following an oral glucose tolerance test in vehicle treated wild-type, vehicle treated db/db, and db/db mice administered 0.05 mg/kg <b>1</b> or <b>3</b> (<i>n</i> = 5) (B). The compounds were administered three hours prior to the oral glucose challenge. *, <i>P</i> < 0.05 and **, <i>P</i> < 0.001 versus diabetic control. Error bars show mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Pro-Soft Drug Toxicity vs <b>1</b> Alone</h3><div class="NLM_p">The toxicities of <b>1</b> and <b>3</b> were compared in a dose escalation study in Fischer rats, the most sensitive species and most reliable indicator of the severe toxicity of <b>1</b>. We and others have previously found that in rats <b>1</b> has an LD<sub>50</sub> of ∼0.5 mg/kg. Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a> confirms the LD<sub>50</sub> for <b>1</b> while showing that the equivalent dose of <b>3</b> exhibited no obvious toxicity. The LD<sub>50</sub> for <b>3</b> appears to be approximately 2- to 3-fold higher.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0012.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Toxicity of the pro-soft drug (compound <b>3</b>) vs the dipeptide inhibitor (compound <b>1</b>) in rats. Percent survival after 24 h was assessed in Fischer rats following oral administration of 0.15, 0.5, or 1.5 mg/kg of <b>1</b> or <b>3</b> (<i>n</i> = 4).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Although <b>3</b> is both safer and more effective than <b>1</b> as an antihyperglycemic agent, the gains are smaller than might have been hoped for. DPPIV is widely distributed throughout the body and therefore is probably not the optimal target for showcasing the workings of a drug concept designed to focus pharmacological activity at a selected site. A tumor, for example, would provide a better target and a construct that is selectively activated at the tumor should show greater gains in efficacy and safety. Nevertheless, even the modest gains of the magnitude achieved here might be sufficient to make a tumor-selective construct an attractive clinical candidate for cancer. The design and testing of such tumor-specific pro-soft derivatives of <b>1</b>, and of other boronic acids that have anticancer activity such as bortezomib, is underway.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58620" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58620" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Here we have demonstrated that the pH dependent cyclization reaction intrinsic to <b>1</b> confers unique properties on prodrugs of <b>1</b>, including a soft drug like activity such that prodrugs of <b>1</b> are actually pro-soft drugs. The workings of the pro-soft design is demonstrated in vitro and in vivo with a construct activated by and targeted to DPPIV. The concept outlined here is not limited to constructs of <b>1</b> but can be applied to wide variety of other inhibitors and targets. Perhaps the most useful applications will be in tissue-specific targeting. For example, bortezomib is a dipeptide boronic acid approved for the treatment of multiple myeloma.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> It targets the proteasome, an enzyme complex found in all cells and tissues, and has a very narrow therapeutic window, most likely from toxicities arising from on-target inhibition in off-target normal cells and tissues. This perhaps explains why bortezobib has thus far not shown efficacy against solid tumors. The pro-soft strategy, with its potential for tissue-specific targeting, could help to make proteasome inhibition an effective strategy against solid tumors.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58740" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58740" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Synthesis of Boronic Acid Dipeptides</h3><div class="NLM_p">Synthesis of all X<sub>aa</sub>-boroPro dipeptides was performed essentially as described previously, except that the N- and C-terminal protection groups of the N-Boc-(<i>S</i>)-X<sub>aa</sub>-(<i>R</i>)-boroPro-(1<i>S</i>,2<i>S</i>,3<i>R</i>,5<i>S</i>)-pinanediol ester products were removed simultaneously.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Specifically, to a stirred solution of the protected product in CH<sub>2</sub>Cl<sub>2</sub> cooled to −78 °C, an equimolar amount of a 1.0 M solution of BCl<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> was added. After 1 h, the product was extracted into water and purified on a Supelco Discovery-C18 column, eluting with water (0.1% TFA) and acetonitrile (0.08% TFA). Lyophilization yielded the free dipeptide boronic acids, the identities of which were confirmed by <sup>1</sup>H NMR and LC/MS, using the latter to assess a level of relative purity ≥95%.</div><div class="NLM_p last">NMR spectra of the compounds in D<sub>2</sub>O solution were recorded on a Bruker Avance 300 MHz spectrometer. Chemical shifts were reported relative to DSS. Mass spectra and HPLC retention times were recorded on a Hewlett-Packard HP LC/MSD system with UV detector (monitoring at 215 and 254 nm), using a Discovery C18 569232-U RP-HPLC column (12.5 cm, 4.6 mm, 5 μm) with solvent gradient (A) water (0.1% TFA) and (B) acetonitrile (0.08% TFA) flowing at 0.5 mL/min. Unless otherwise noted, all HPLC retention times are given for an eluent gradient 2% B for the first 5 min, 2−98% B over 10 min and 98%B for the final 10 min.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Valinyl-<span class="smallcaps smallerCapital">l</span>-boroproline (<b>1</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (D<sub>2</sub>O) δ 0.98 (d, <i>J</i> = 7.0 Hz, 3H, C<i>H</i><sub><i>3</i></sub>CHCH<sub>3</sub>), 1.08 (d, <i>J</i> = 7.0 Hz, 3H, CH<sub>3</sub>CHC<i>H</i><sub><i>3</i></sub>), 1.60−2.34 (m, 5H, CH<sub>3</sub>C<i>H</i>CH<sub>3</sub> and BCHC<i>H</i><sub>2</sub>C<i>H</i><sub>2</sub>), 3.03−3.09 (m, 1H, CH<sub>2</sub>C<i>H</i>B), 3.43−3.75 (m, 2H, CH<sub>2</sub>C<i>H</i><sub>2</sub>N), 4.12 (d, <i>J</i> = 6.5 Hz, 1H, H<sub>2</sub>NC<i>H</i>CO). LC-MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> (rel intensity): 393.3 ([2 × (M − H<sub>2</sub>O) + H]<sup>+</sup>, 60); 197.1 [M − H<sub>2</sub>O + H]<sup>+</sup>, tr = 11.1 min.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Alaninyl-<span class="smallcaps smallerCapital">l</span>-boroproline (<b>2</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (D<sub>2</sub>O) δ 1.48 (d, <i>J</i> = 7.0 Hz, 3H, C<i>H</i><sub><i>3</i></sub>CHNH<sub>2</sub>), 1.67−2.15 (m, 4H, BCHC<i>H</i><sub>2</sub>C<i>H</i><sub>2</sub>), 3.03−3.09 (m, 1H, CH<sub>2</sub>C<i>H</i>B), 3.41−3.72 (m, 2H, CH<sub>2</sub>C<i>H</i><sub>2</sub>N), 4.31 (q, <i>J</i> = 7.0 Hz, 1H, H<sub>2</sub>NC<i>H</i>CO). LC-MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> (rel intensity): 337.2 [2 × (M − H<sub>2</sub>O) + H]<sup>+</sup>; 169.0 [M − H<sub>2</sub>O + H]<sup>+</sup>, tr = 5.9 min.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Synthesis of Free Boronic Acid Pro-Soft Drugs</h3><div class="NLM_p last">All protected amino acids, with the exception of the boroPro derivative, which was synthesized as described above, were purchased from Novabiochem. Peptide coupling reactions were performed twice per final product, with N-Boc-X<sub>aa</sub>-OH and H-X<sub>aa</sub>-OMe used for the N-terminal dipeptide and N-Boc-X<sub>aa</sub>-OH and the H-boroX<sub>aa</sub>-(1<i>S</i>,2<i>S</i>,3<i>R</i>,5<i>S</i>)-pinanediol ester for the C-terminal dipeptide. To a stirred solution of the N-terminal protected product in a 1:1 solution of water:THF at 0 °C, 5 equiv of LiOH were added. The reaction was quenched after 1 h with 12 N HCl and the product extracted into EtOAc. Evaporation of the solvent yielded the crude N-Boc-(X<sub>aa</sub>)<sub>2</sub>-OH product. The Boc group of the C-terminal dipeptide was removed as described previously, yielding the H-X<sub>aa</sub>-boroPro pinanediol ester. The N- and C-terminal dipeptides were coupled as described previously, yielding the crude N-Boc-(X<sub>aa</sub>)<sub>3</sub>-boroPro pinanediol ester. The protection groups were removed as previously described for the dipeptide inhibitors, yielding the boronic acid pro-soft drugs, the identities of which were confirmed by <sup>1</sup>H NMR and LC/MS, using the latter to assess a level of relative purity ≥95%.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Cyclohexyl(glycinyl)-prolinyl-valinyl-<span class="smallcaps smallerCapital">l</span>-boroproline (<b>3</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (D<sub>2</sub>O) δ 0.98 (6H, C<i>H</i><sub><i>3</i></sub>CHC<i>H</i><sub><i>3</i></sub>), 1.10−1.80 (11H, H<sub>2</sub>NCHC<i>H<sub>2</sub></i>C<i>H<sub>2</sub></i>C<i>H<sub>2</sub></i>C<i>H<sub>2</sub></i>C<i>H<sub>2</sub></i> and C<i>H</i><sub>2</sub>CHB), 1.84−2.29 (9H, C<i>H</i><sub><i>2</i></sub>C<i>H</i><sub><i>2</i></sub>CHCO, C<i>H</i><sub><i>2</i></sub>C<i>H</i><sub>2</sub>CHB, and CH<sub>3</sub>C<i>H</i>CH<sub>3</sub>), 2.95 (1H, CH<sub>2</sub>C<i>H</i>B), 3.52−3.82 (4H, N<i>CH</i><sub><i>2</i></sub>CH<sub>2</sub> and C<i>H<sub>2</sub></i>CH<sub>2</sub>CH<sub>2</sub>CHB), 4.15 (1H, H<sub>2</sub>NC<i>H</i>CO), 4.38 (1H, HNC<i>H</i>CO), 4.53 (1H, NC<i>H</i>CO). LC-MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> (rel intensity): 433.3 [M − H<sub>2</sub>O + H]<sup>+</sup>, tr = 12.7 min.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Phenylalaninyl-prolinyl-alaninyl-<span class="smallcaps smallerCapital">l</span>-boroproline (<b>4</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (D<sub>2</sub>O) δ 1.38 (3H, HNCHC<i>H</i><sub><i>3</i></sub>), 1.69−2.29 (8H, C<i>H</i><sub><i>2</i></sub>C<i>H</i><sub><i>2</i></sub>CHCO and C<i>H</i><sub><i>2</i></sub>C<i>H</i><sub>2</sub>CHB), 3.01 (1H, CH<sub>2</sub>C<i>H</i>B), 3.14−3.82 (6H, N<i>CH</i><sub><i>2</i></sub>CH<sub>2</sub>, C<i>H</i><sub><i>2</i></sub>CH<sub>2</sub>CH<sub>2</sub>CHB, and H<sub>2</sub>NCHC<i>H</i><sub><i>2</i></sub>C), 4.03 (1H, H<sub>2</sub>NC<i>H</i>CO), 4.24 (1H, HNC<i>H</i>CO), 4.52 (1H, NC<i>H</i>CO), 7.38 (5H, aromatic H). LC-MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> (rel intensity): 413.3 [M − H<sub>2</sub>O + H]<sup>+</sup>, tr = 12.1 min.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Synthesis of the Succinylated Boronic Acid Pro-Soft Drug</h3><div class="NLM_p last">Following synthesis of the appropriate N-Boc-Ala-Ala-Pro-Phe-Ala-boroPro-(1<i>S</i>,2<i>S</i>,3<i>R</i>,5<i>S</i>)-pinanediol ester as using the pro-soft drug synthesis protocol described above, the Boc group was removed as before. The resulting H-Ala-Ala-Pro-Phe-Ala-boroPro pinanediol ester was dissolved in a 5:1 solution of CH<sub>2</sub>Cl<sub>2</sub>:DMF. This was treated with 1.25 equiv of succinic anhydride and TEA, yielding the Suc-Ala-Ala-Pro-Phe-Ala-boroPro pinanediol ester after 18 h. Removal of the pinanediol group yielded the free final product, the identity of which was confirmed by <sup>1</sup>H NMR and LC/MS, using the latter to assess a level of relative purity ≥95%.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Succinyl-alaninyl-alaninyl-prolinyl-phenylalaninyl-alaninyl-<span class="smallcaps smallerCapital">l</span>-boroproline (<b>5</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (D<sub>2</sub>O) δ 1.32 (9H, H<sub>2</sub>NCHC<i>H</i><sub><i>3</i></sub> and HNCHC<i>H</i><sub><i>3</i></sub>), 1.54−2.09 (8H, C<i>H</i><sub><i>2</i></sub>C<i>H</i><sub><i>2</i></sub>CHCO and C<i>H</i><sub><i>2</i></sub>C<i>H</i><sub>2</sub>CHB), 2.53−2.62 (4H, HOCOC<i>H</i><sub><i>2</i></sub>C<i>H</i><sub><i>2</i></sub>), 2.96 (1H, CH<sub>2</sub>C<i>H</i>B), 3.13−3.72 (6H, N<i>CH</i><sub><i>2</i></sub>CH<sub>2</sub>, C<i>H</i><sub><i>2</i></sub>CH<sub>2</sub>CH<sub>2</sub>CHB, and H<sub>2</sub>NCHC<i>H</i><sub><i>2</i></sub>C), 4.24−4.56 (5H, H<sub>2</sub>NC<i>H</i>CO, HNC<i>H</i>CO, and NC<i>H</i>CO), 7.38 (5H, aromatic H). LC-MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> (rel intensity): 637.6 [M − 2·H<sub>2</sub>O + H]<sup>+</sup>, tr = 14.0 min.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> In Vitro DPPIV Enzyme Assay</h3><div class="NLM_p">Enzymatic activity of purified DPPIV was measured at either 25 or 37 °C on a Molecular Devices SPECTRAmax 340PC<sup>384</sup> microtiter plate reader, monitoring the absorbance at 410 nm and using H-Ala-Pro-pNA, purchased from Bachem, as the chromogenic substrate. The reaction mixture contained 0.3 mM substrate, approximately 1 nM DPPIV, 0.1 M HEPES, 0.14 M NaCl buffer, pH 7.4 or 8.0, and a suitable amount of inhibitor or pro-soft drug (ranging between 10<sup>−5</sup> and 10<sup>−11</sup> M) in a total volume of 310 μL.</div><div class="NLM_p last">The IC<sub>50</sub> value is defined as the concentration of inhibitor required to reduce the DPPIV activity by 50% after a 10 min preincubation with the enzyme at 25 or 37 °C prior to addition of the substrate. Inhibitor stock solutions were prepared in either HCl solution, pH 2.0, or buffer, pH 7.4 or 8.0. Stock solutions were diluted with 0.1 M HEPES, 0.14 M NaCl buffer, pH 7.4 or 8.0, as required, immediately prior to the commencement of the experiment.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> α-Chymotrypsin/DPPIV Enzyme Assay</h3><div class="NLM_p last">The assay was similar to the DPPIV enzyme assay, except that the pro-soft drug was incubated with 0.1 mM α-chymotrypsin, purchased from Sigma, for 0, 0.5, 1, 2, 4, 6, or 24 h prior to the addition of the purified DPPIV enzyme.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Pro-Soft Drug Cleavage by Purified DPPIV in Vitro</h3><div class="NLM_p">The following three reactions were set up, all of which were prepared in 0.1 M HEPES, 0.14 M NaCl buffer, pH 8.0 DPP IV buffer:</div><ul class="NLM_list-list_type-label"><li><p class="inline"><i>Enzyme/dipeptide control</i>: 100 μL of 2 μM DPP IV stock, 100 μL 20 mM Chg-Pro.</p></li><li><p class="inline"><i>No enzyme control</i>: 100 μL of DPP IV buffer, 100 μL 10 mM <b>3</b>.</p></li><li><p class="inline"><i>Enzyme/pro-soft drug sample</i>: 100 μL DPP IV stock, 100 μL 10 mM <b>3</b>.</p></li></ul><div class="NLM_p last">The samples were incubated for 10 min at 25 °C, following which they were transferred to a C<sub>18</sub> column, eluted with 5 mL 2% acetonitrile, and lyophilized. The samples were analyzed by reverse-phase HPLC-MS on a Thermo Finnigan LCQ Duo, scanning an <i>m</i>/<i>z</i> range of 254.5−255.5, which corresponded to the mass of the Chg-Pro dipeptide.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Assay for Pro-Soft Drug Cleavage in Vivo</h3><div class="NLM_p last">Three wild-type C57BL/6 (CD26<sup>+/+</sup>) or DPPIV knockout (CD26<sup>−/−</sup>) mice<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> were acclimated for at least one week prior to the study. The mice were given an intraperitoneal injection of 50 μg of <b>3</b> in 400 μL PBS. After 5 min, blood samples were collected via cardiac puncture, treated with 10% TCA, and spun down. The resulting supernatant was collected and the samples analyzed by reverse-phase HPLC-MS on a Thermo Finnigan LCQ Duo, quantifying the peaks corresponding to the intact pro-soft drug in the resulting base peak chromatograms.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Serum DPPIV Activity Assay</h3><div class="NLM_p last">To 10 μL of the serum samples provided by MDS Pharma Services, 150 μL of 3 mM H-Ala-Pro-pNA Bachem in 0.1 M HEPES, 0.14 M NaCl buffer, pH 8.0 was added. The absorbance at 410 nm was measured on a Molecular Devices SPECTRAmax 340PC<sup>384</sup> plate reader following a 1 h incubation at 25 °C. Relative DPPIV activity was based on the <i>A</i><sub>410</sub> of the diabetic control equaling 100% serum enzyme activity.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Oral Glucose Tolerance Test in Diabetic Mice</h3><div class="NLM_p last">The following experiment was performed by MDS Pharma Services, Saint-Laurent, Quebéc, Canada. Briefly, 21 diabetic male mice (C57BL/KS01HSD-Leprdb) and 7 nondiabetic male mice (C57BL/6NHHsd) were acclimated for 3 weeks prior to the study. Following a 4 h fasting period, 7 mice per group were dosed via oral gavage with 2 mL/kg of a 5.8, 23.3, 58.3, or 116.7 μM solution of either <b>1</b> or <b>3</b>. This is equivalent to dosing each animal with 0.0025, 0.01, 0.025, or 0.05 mg/kg of free inhibitor. As controls, 7 diabetic and 7 nondiabetic mice were treated with vehicle (H<sub>2</sub>O) alone. Three hours following dose administration, a single oral dose (1 g/kg) of glucose (Dextrose USP, Abbott Laboratories) was administered. At predose, 15, 30, 60, 120, and 240 min post-Rx glucose, blood samples were collected from 5 mice/group for blood glucose testing on a calibrated hand-held glucometer, and serum samples were collected from the remaining 2 mice/group at 60 and 240 min post-Rx glucose.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Toxicity Study in Fisher Rats</h3><div class="NLM_p last">The following experiment was performed by the Tufts Division of Laboratory Animal Medicine. Briefly, 24 male Fischer rats (F344) were acclimated for 1 week prior to the study. Four rats per group were dosed by oral gavage with 2 mL/kg of a 0.35, 1.17, or 3.5 mM solution of either <b>1</b> or <b>3</b>. This is equivalent to dosing each animal with 0.15, 0.5, or 1.5 mg/kg of free inhibitor. The animals were monitored over a 24 h period, during which time the mortality rate was recorded.</div></div></div><div class="NLM_back"><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30318" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30318" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William W. Bachovchin</span> - <span class="hlFld-Affiliation affiliation">Tufts University Sackler School of Graduate Biomedical Sciences, Department of Biochemistry, 136 Harrison Avenue, Boston, Massachusetts 02111, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0e79676262676f63206c6f6d6661786d6667604e7a7b687a7d206b6a7b"><span class="__cf_email__" data-cfemail="a2d5cbcececbc3cf8cc0c3c1cacdd4c1cacbcce2d6d7c4d6d18cc7c6d7">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah E. Poplawski</span> - <span class="hlFld-Affiliation affiliation">Tufts University Sackler School of Graduate Biomedical Sciences, Department of Biochemistry, 136 Harrison Avenue, Boston, Massachusetts 02111, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jack H. Lai</span> - <span class="hlFld-Affiliation affiliation">Tufts University Sackler School of Graduate Biomedical Sciences, Department of Biochemistry, 136 Harrison Avenue, Boston, Massachusetts 02111, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David G. Sanford</span> - <span class="hlFld-Affiliation affiliation">Tufts University Sackler School of Graduate Biomedical Sciences, Department of Biochemistry, 136 Harrison Avenue, Boston, Massachusetts 02111, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James L. Sudmeier, Wengen Wu</span> - <span class="hlFld-Affiliation affiliation">Tufts University Sackler School of Graduate Biomedical Sciences, Department of Biochemistry, 136 Harrison Avenue, Boston, Massachusetts 02111, United States</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="testing" data-doi="10.1021/jm100972f" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55665" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55665" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank MDS Pharma Services in Saint-Laurent, Quebéc, for performing all of the mouse experiments, and we thank the DLAM at Tufts University for carrying out the rat experiments. This work was supported by Arisaph Pharmaceuticals, Inc.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i30" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i30"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i31" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i31"> Abbreviations Used</h2><tr><td class="NLM_term">GLP-1</td><td class="NLM_def"><p class="first last">glucagon-like peptide-1</p></td></tr><tr><td class="NLM_term">GIP</td><td class="NLM_def"><p class="first last">glucose-dependent insulinotropic polypeptide</p></td></tr><tr><td class="NLM_term">DPPIV</td><td class="NLM_def"><p class="first last">dipeptidyl peptidase IV</p></td></tr><tr><td class="NLM_term">DPP8</td><td class="NLM_def"><p class="first last">dipeptidyl peptidase 8</p></td></tr><tr><td class="NLM_term">DPP9</td><td class="NLM_def"><p class="first last">dipeptidyl peptidase 9</p></td></tr><tr><td class="NLM_term">DPPII</td><td class="NLM_def"><p class="first last">dipeptidyl peptidase II</p></td></tr><tr><td class="NLM_term">FAP</td><td class="NLM_def"><p class="first last">fibroblast activation protein</p></td></tr><tr><td class="NLM_term">PREP</td><td class="NLM_def"><p class="first last">prolyl oligopeptidase</p></td></tr><tr><td class="NLM_term">Chg</td><td class="NLM_def"><p class="first last">cyclohexyl(glycine)</p></td></tr><tr><td class="NLM_term">MTD</td><td class="NLM_def"><p class="first last">maximum tolerated dose</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>i</sub></td><td class="NLM_def"><p class="first last">inhibition constant</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">median inhibition concentration</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28854" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28854" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 28 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Adams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wantanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallner, B. P.</span><span> </span><span class="NLM_article-title">PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">5471</span><span class="NLM_x">–</span> <span class="NLM_lpage">5480</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=5471-5480&author=S.+Adamsauthor=G.+T.+Millerauthor=M.+I.+Jessonauthor=T.+Wantanabeauthor=B.+Jonesauthor=B.+P.+Wallner&title=PT-100%2C+a+small+molecule+dipeptidyl+peptidase+inhibitor%2C+has+potent+antitumor+effects+and+augments+antibody-mediated+cytotoxicity+via+a+novel+immune+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DG.%2BT.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DWantanabe%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DWallner%26aufirst%3DB.%2BP.%26atitle%3DPT-100%252C%2520a%2520small%2520molecule%2520dipeptidyl%2520peptidase%2520inhibitor%252C%2520has%2520potent%2520antitumor%2520effects%2520and%2520augments%2520antibody-mediated%2520cytotoxicity%2520via%2520a%2520novel%2520immune%2520mechanism%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D5471%26epage%3D5480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Kubota, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flentke, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stollar, B. D.</span><span> </span><span class="NLM_article-title">Involvement of dipeptidyl peptidase IV in an in vivo immune response</span> <span class="citation_source-journal">Clin. Exp. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1111%2Fj.1365-2249.1992.tb06931.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=1353423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADyaK3sXlsFCq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=192-197&author=T.+Kubotaauthor=G.+R.+Flentkeauthor=W.+W.+Bachovchinauthor=B.+D.+Stollar&title=Involvement+of+dipeptidyl+peptidase+IV+in+an+in+vivo+immune+response"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of dipeptidyl peptidase IV in an in vivo immune response</span></div><div class="casAuthors">Kubota, T.; Flentke, G. R.; Bachovchin, W. W.; Stollar, B. D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">192-7</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    </div><div class="casAbstract">Dipeptidyl peptidase IV (DP IV) is a serine protease that selectively cleaves X-Pro dipeptides from polypeptides and proteins.  Among blood cells, this enzyme occurs preferentially on the surface of CD4+ T cells and the amt. of enzyme activity increases with T cell activation.  In previous work, two potent and specific peptidyl-boronic acid inhibitors of DP IV, Ala-boroPro and Pro-boroPro, were synthesized and Pro-boroPro was shown to suppress antigen-specific proliferative responses of T cells in vitro.  This study tested the in vivo effects of these inhibitors.  The injection (s.c.) of Ala-boroPro or Pro-boroPro into BALB/c mice inhibited DP IV activity in serum and spleen cell suspensions.  Repeated injections of more than 10 μg of Ala-boroPro or Pro-boroPro at 12 h intervals maintained in vivo DP IV activity at less than 30% of the normal level.  Repeated injections of the inhibitors during the primary, secondary or tertiary immune response to bovine serum albumin (BSA) reduced anti-BSA antibody prodn.  Without inhibitor, immunization with BSA was followed by a temporary decrease in serum DP IV activity and then by enhanced serum enzyme activity after several days.  These results provide the first direct evidence that DP IV plays an important role in immune responses in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkpFlIa1M-1rVg90H21EOLACvtfcHk0ljvuxNyjdwwwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsFCq&md5=4eadb0f364cad70e7bdae9f37342495e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2249.1992.tb06931.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2249.1992.tb06931.x%26sid%3Dliteratum%253Aachs%26aulast%3DKubota%26aufirst%3DT.%26aulast%3DFlentke%26aufirst%3DG.%2BR.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26aulast%3DStollar%26aufirst%3DB.%2BD.%26atitle%3DInvolvement%2520of%2520dipeptidyl%2520peptidase%2520IV%2520in%2520an%2520in%2520vivo%2520immune%2520response%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D1992%26volume%3D89%26spage%3D192%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Kelly, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutts, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, R. J.</span><span> </span><span class="NLM_article-title">Immunosuppressive boronic acid dipeptides: correlation between conformation and activity</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">12637</span><span class="NLM_x">–</span> <span class="NLM_lpage">12638</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00079a074" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1993&pages=12637-12638&author=T.+A.+Kellyauthor=J.+Adamsauthor=W.+W.+Bachovchinauthor=R.+W.+Bartonauthor=S.+J.+Campbellauthor=S.+J.+Couttsauthor=C.+A.+Kennedyauthor=R.+J.+Snow&title=Immunosuppressive+boronic+acid+dipeptides%3A+correlation+between+conformation+and+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fja00079a074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00079a074%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DT.%2BA.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26aulast%3DBarton%26aufirst%3DR.%2BW.%26aulast%3DCampbell%26aufirst%3DS.%2BJ.%26aulast%3DCoutts%26aufirst%3DS.%2BJ.%26aulast%3DKennedy%26aufirst%3DC.%2BA.%26aulast%3DSnow%26aufirst%3DR.%2BJ.%26atitle%3DImmunosuppressive%2520boronic%2520acid%2520dipeptides%253A%2520correlation%2520between%2520conformation%2520and%2520activity%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1993%26volume%3D115%26spage%3D12637%26epage%3D12638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Mentlein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallwitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, W. E.</span><span> </span><span class="NLM_article-title">Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7−36)amide, peptide histidine methionine and is responsible for their degradation in human serum</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">214</span><span class="NLM_x">, </span> <span class="NLM_fpage">829</span><span class="NLM_x">–</span> <span class="NLM_lpage">835</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1111%2Fj.1432-1033.1993.tb17986.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=8100523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADyaK3sXks1elsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=1993&pages=829-835&author=R.+Mentleinauthor=B.+Gallwitzauthor=W.+E.+Schmidt&title=Dipeptidyl-peptidase+IV+hydrolyses+gastric+inhibitory+polypeptide%2C+glucagon-like+peptide-1%287%E2%88%9236%29amide%2C+peptide+histidine+methionine+and+is+responsible+for+their+degradation+in+human+serum"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Dipeptidyl-peptidase IV hydrolyzes gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum</span></div><div class="casAuthors">Mentlein, Rolf; Gallwitz, Baptist; Schmidt, Wolfgang E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">829-35</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    </div><div class="casAbstract">Peptides of the glucagon/VIP family share a considerable sequence similarity at their N-terminus.  They either start with Tyr-Ala, His-Ala or His-Ser which might be in part potential targets for dipeptidyl-peptidase IV, a highly specialized aminopeptidase removing dipeptides only from peptides with N-terminal penultimate proline or alanine.  GH-releasing factor(1-29)amide and gastric inhibitory peptide/glucose-dependent insulinotropic peptide (GIP) with terminal Tyr-Ala as well as glucagon-like peptide-1(7-36)amide/insulinotropin [GLP-1(7-36)amide] and peptide histidine methionine (PHM) with terminal His-Ala were hydrolyzed to their des-Xaa-Ala derivs. by dipeptidyl-peptidase IV purified from human placenta.  VIP with terminal His-Ser was not degraded by the peptidase.  The kinetics of the hydrolysis of GIP, GLP-1(7-36)amide and PHM were analyzed in detail.  For these peptides Km values of 4-34 μM and Vmax values of 0.6-3.8 μmol/min/mg protein were detd. for the purified peptidase which should allow their enzymic degrdn. also at physiol., nanomolar concns.  When human serum was incubated with GIP or GLP-1(7-36)amide the same fragments as with the purified dipeptidyl-peptidase IV, namely the des-Xaa-Ala peptides and Tyr-Ala in the case of GIP or His-Ala in the case of GLP-1(7-36)amide, were identified as the main degrdn. products of these peptide hormones.  Incorporation of inhibitors specific for dipeptidyl-peptidase IV, 1 mM Lys-pyrrolidide or 0.1 mM diprotin A (Ile-Pro-Ile), completely abolished the prodn. of these fragments by serum.  It is concluded that dipeptidyl-peptidase IV initiates the metab. of GIP and GLP-1(7-36)amide in human serum.  Since an intact N-terminus is obligate for the biol. activity of the members of the glucagon/VIP peptide family [e.g., GIP(3-42) is known to be inactive to release insulin in the presence of glucose as is intact GIP], dipeptidyl-peptidase-IV action inactivates these peptide hormones.  The relevance of this finding for their inactivation and their detn. by immunoassays is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaIzMbUUoh9LVg90H21EOLACvtfcHk0ljvuxNyjdwwwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXks1elsLs%253D&md5=dd06411585d4e8bb42d5b093e895b900</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1993.tb17986.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1993.tb17986.x%26sid%3Dliteratum%253Aachs%26aulast%3DMentlein%26aufirst%3DR.%26aulast%3DGallwitz%26aufirst%3DB.%26aulast%3DSchmidt%26aufirst%3DW.%2BE.%26atitle%3DDipeptidyl-peptidase%2520IV%2520hydrolyses%2520gastric%2520inhibitory%2520polypeptide%252C%2520glucagon-like%2520peptide-1%25287%25E2%2588%259236%2529amide%252C%2520peptide%2520histidine%2520methionine%2520and%2520is%2520responsible%2520for%2520their%2520degradation%2520in%2520human%2520serum%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1993%26volume%3D214%26spage%3D829%26epage%3D835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Kieffer, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pederson, R. A.</span><span> </span><span class="NLM_article-title">Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">3585</span><span class="NLM_x">–</span> <span class="NLM_lpage">3596</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=1995&pages=3585-3596&author=T.+J.+Kiefferauthor=C.+H.+McIntoshauthor=R.+A.+Pederson&title=Degradation+of+glucose-dependent+insulinotropic+polypeptide+and+truncated+glucagon-like+peptide+1+in+vitro+and+in+vivo+by+dipeptidyl+peptidase+IV"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKieffer%26aufirst%3DT.%2BJ.%26aulast%3DMcIntosh%26aufirst%3DC.%2BH.%26aulast%3DPederson%26aufirst%3DR.%2BA.%26atitle%3DDegradation%2520of%2520glucose-dependent%2520insulinotropic%2520polypeptide%2520and%2520truncated%2520glucagon-like%2520peptide%25201%2520in%2520vitro%2520and%2520in%2520vivo%2520by%2520dipeptidyl%2520peptidase%2520IV%26jtitle%3DEndocrinology%26date%3D1995%26volume%3D136%26spage%3D3585%26epage%3D3596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Choy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, S.</span><span> </span><span class="NLM_article-title">Sitagliptin: a novel drug for the treatment of type 2 diabetes</span> <span class="citation_source-journal">Cardiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">271</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1097%2FCRD.0b013e318123f771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=17700385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A280%3ADC%252BD2svovFensw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=264-271&author=M.+Choyauthor=S.+Lam&title=Sitagliptin%3A+a+novel+drug+for+the+treatment+of+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Sitagliptin: a novel drug for the treatment of type 2 diabetes</span></div><div class="casAuthors">Choy Mary; Lam Sum</div><div class="citationInfo"><span class="NLM_cas:title">Cardiology in review</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">264-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type 2 diabetes mellitus is a common chronic disease that causes significant morbidity and mortality worldwide.  The primary goal of treatment is to target glycemic control by maintaining the glycosylated hemoglobin level near 6-7% without predisposing patients to hypoglycemia.  Diabetes results from a combination of increased hepatic glucose production, decreased insulin secretion from beta cells, and insulin resistance in the peripheral tissues.  Currently available antidiabetic agents work by different mechanisms to lower blood glucose levels.  Unfortunately, each of them has its tolerability and safety concerns that limit its use and dose titration.  Sitagliptin is the first antidiabetic agent from the class of dipeptidyl peptidase-4 enzyme inhibitors.  It increases the amount of circulating incretins, which stimulate insulin secretion and inhibit glucose production.  Sitagliptin was approved by the US Food and Drug Administration (FDA) for use with diet and exercise to improve glycemic control in adult patients with type 2 diabetes.  It can be used alone or in combination with metformin or a thiazolidinedione (pioglitazone or rosiglitazone) when treatment with either drug alone provides inadequate glucose control.  The usual adult dose is 100 mg once daily.  A dose of 25-50 mg once daily is recommended for patients with moderate-to-severe renal impairment.  In randomized, placebo-controlled trials that lasted for up to 6 months, sitagliptin lowered glycosylated hemoglobin levels by 0.5-0.8%.  In a 52-week clinical trial, sitagliptin was shown to be noninferior to glipizide as an add-on agent in patients inadequately controlled on metformin alone.  Sitagliptin was well tolerated with the most common side effects being gastrointestinal complaints (up to 16%), including abdominal pain, nausea and diarrhea; hypoglycemia and body weight gain occurred at similar rates compared with placebo.  Overall, sitagliptin provides a treatment option for patients with type 2 diabetes as a monotherapy, or as an adjunct to metformin or a thiazolidinedione when patients achieve inadequate glycemic control while on either of the agents.  It is also an alternative therapy for those patients who have contraindications or intolerability to other antidiabetic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQE6VB-Pf2cTq91pGlMMoT5fW6udTcc2eYwMJ4jX19HP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svovFensw%253D%253D&md5=f4f20ba2241dacf7e55c26d3c5cec66c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2FCRD.0b013e318123f771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCRD.0b013e318123f771%26sid%3Dliteratum%253Aachs%26aulast%3DChoy%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DS.%26atitle%3DSitagliptin%253A%2520a%2520novel%2520drug%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DCardiol.%2520Rev.%26date%3D2007%26volume%3D15%26spage%3D264%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Traynor, K.</span><span> </span><span class="NLM_article-title">FDA approves saxagliptin for type 2 diabetes</span> <span class="citation_source-journal">Am. J. Health Syst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1513</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=19710428" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2009&pages=1513&author=K.+Traynor&title=FDA+approves+saxagliptin+for+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTraynor%26aufirst%3DK.%26atitle%3DFDA%2520approves%2520saxagliptin%2520for%2520type%25202%2520diabetes%26jtitle%3DAm.%2520J.%2520Health%2520Syst.%26date%3D2009%26volume%3D66%26spage%3D1513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Croxtall, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keam, S. J.</span><span> </span><span class="NLM_article-title">Vildagliptin: a review of its use in the management of type 2 diabetes mellitus</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">2387</span><span class="NLM_x">–</span> <span class="NLM_lpage">2409</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=2387-2409&author=J.+D.+Croxtallauthor=S.+J.+Keam&title=Vildagliptin%3A+a+review+of+its+use+in+the+management+of+type+2+diabetes+mellitus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCroxtall%26aufirst%3DJ.%2BD.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DVildagliptin%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520management%2520of%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DDrugs%26date%3D2008%26volume%3D68%26spage%3D2387%26epage%3D2409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Horie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, M.</span><span> </span><span class="NLM_article-title">Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo</span> <span class="citation_source-journal">Trials</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=82&author=Y.+Horieauthor=N.+Hayashiauthor=K.+Dugiauthor=M.+Takeuchi&title=Design%2C+statistical+analysis+and+sample+size+calculation+of+a+phase+IIb%2FIII+study+of+linagliptin+versus+voglibose+and+placebo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHorie%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DN.%26aulast%3DDugi%26aufirst%3DK.%26aulast%3DTakeuchi%26aufirst%3DM.%26atitle%3DDesign%252C%2520statistical%2520analysis%2520and%2520sample%2520size%2520calculation%2520of%2520a%2520phase%2520IIb%252FIII%2520study%2520of%2520linagliptin%2520versus%2520voglibose%2520and%2520placebo%26jtitle%3DTrials%26date%3D2009%26volume%3D10%26spage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Pratley, R. E.</span><span> </span><span class="NLM_article-title">Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">512</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1517%2F14656560802694713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=19191685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVaiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=503-512&author=R.+E.+Pratley&title=Alogliptin%3A+a+new%2C+highly+selective+dipeptidyl+peptidase-4+inhibitor+for+the+treatment+of+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes</span></div><div class="casAuthors">Pratley, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">503-512</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Alogliptin is a potent, highly selective dipeptidyl peptidase-4 inhibitor now undergoing clin. testing to support a new drug application for the treatment of type 2 diabetes.  Objective: To provide an overview of the mechanism by which alogliptin reduces hyperglycemia and to summarize the pharmacol., efficacy and safety of the drug.  Methods: A Medline search was conducted and abstrs. and presentations from recent American Diabetes Assocn. and European Assocn. for the Study of Diabetes (EASD) meetings were reviewed.  The results of phase II and phase III human studies were evaluated for clin. efficacy, safety and tolerability in patients with type 2 diabetes.  Results/conclusions: Alogliptin is effective as a treatment for type 2 diabetes, either as monotherapy or in combination with metformin, thiazolidinediones, sulfonylureas and insulin.  It is well tolerated and has an excellent safety profile.  Addnl. studies are needed to evaluate the long-term safety and efficacy of alogliptin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVASaAmsEezrVg90H21EOLACvtfcHk0ljkQkuHClbZ6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVaiurY%253D&md5=26b93655020e344a7a063a25aaed728d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1517%2F14656560802694713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560802694713%26sid%3Dliteratum%253Aachs%26aulast%3DPratley%26aufirst%3DR.%2BE.%26atitle%3DAlogliptin%253A%2520a%2520new%252C%2520highly%2520selective%2520dipeptidyl%2520peptidase-4%2520inhibitor%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2009%26volume%3D10%26spage%3D503%26epage%3D512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Connolly, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanford, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiluwal, A. K</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimare, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maw, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudmeier, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span> </span><span class="NLM_article-title">Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6005</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800390n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6005-13&author=B.+A.+Connollyauthor=D.+G.+Sanfordauthor=A.+K+Chiluwalauthor=S.+E.+Healeyauthor=D.+E.+Petersauthor=M.+T.+Dimareauthor=W.+Wuauthor=Y.+Liuauthor=H.+Mawauthor=Y.+Zhouauthor=Y.+Liauthor=Z.+Jinauthor=J.+L.+Sudmeierauthor=J.+H.+Laiauthor=W.+W.+Bachovchin&title=Dipeptide+boronic+acid+inhibitors+of+dipeptidyl+peptidase+IV%3A+determinants+of+potency+and+in+vivo+efficacy+and+safety"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm800390n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800390n%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DB.%2BA.%26aulast%3DSanford%26aufirst%3DD.%2BG.%26aulast%3DChiluwal%26aufirst%3DA.%2BK%26aulast%3DHealey%26aufirst%3DS.%2BE.%26aulast%3DPeters%26aufirst%3DD.%2BE.%26aulast%3DDimare%26aufirst%3DM.%2BT.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMaw%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DSudmeier%26aufirst%3DJ.%2BL.%26aulast%3DLai%26aufirst%3DJ.%2BH.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26atitle%3DDipeptide%2520boronic%2520acid%2520inhibitors%2520of%2520dipeptidyl%2520peptidase%2520IV%253A%2520determinants%2520of%2520potency%2520and%2520in%2520vivo%2520efficacy%2520and%2520safety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6005%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Narra, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullins, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strzemkowski-Brun, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magalong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiansen, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKee, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egleston, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meropol, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. D.</span><span> </span><span class="NLM_article-title">Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1691</span><span class="NLM_x">–</span> <span class="NLM_lpage">1699</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.4161%2Fcbt.6.11.4874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=18032930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkt1Whsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1691-1699&author=K.+Narraauthor=S.+R.+Mullinsauthor=H.+O.+Leeauthor=B.+Strzemkowski-Brunauthor=K.+Magalongauthor=V.+J.+Christiansenauthor=P.+A.+McKeeauthor=B.+Eglestonauthor=S.+J.+Cohenauthor=L.+M.+Weinerauthor=N.+J.+Meropolauthor=J.+D.+Cheng&title=Phase+II+trial+of+single+agent+Val-boroPro+%28talabostat%29+inhibiting+fibroblast+activation+protein+in+patients+with+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer</span></div><div class="casAuthors">Narra, Kalyani; Mullins, Stefanie R.; Lee, Hyung-Ok; Strzemkowski-Brun, Brenda; Magalong, Kimberly; Christiansen, Victoria J.; McKee, Patrick A.; Egleston, Brian; Cohen, Steven J.; Weiner, Louis M.; Meropol, Neal J.; Cheng, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1691-1699</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Purpose: Fibroblost Activation Protein (FAP) is a tumor fibroblast protease that has been shown to potentiate colorectal cancer growth.  The clin. impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clin. inhibitor of FAP enzymic activity, in a phase II study of patients with metastatic colorectal cancer.  Methods: Patients with metastatic colorectal cancer who had previously received systemic chemotherapies were treated with single agent Val-boroPro 200 μg p.o. BID continuously.  Eligibility included measurable disease, performance status of 0 to 2, and adequate organ function.  Lab. correlates evaluated the pharmacodynamic effects of Val-boroPro on FAP enzymic function in the peripheral blood.  Results: Twenty-eight patients (median age 62; 12 males, 16 females) were enrolled in this study.  There were no objective responses.  Six of 28 (21%) patients had stable disease for a median of 25 wk (range 11-38 wk).  Lab. anal. demonstrated significant, although incomplete inhibition of FAP enzymic activity in the peripheral blood.  Conclusion: This phase II trial of Val-boroPro demonstrated minimal clin. activity in patients with previously treated metastatic colorectal cancer.  However it provides the initial proof-of-concept that physiol. inhibition of FAP activity can be accomplished in patients with colorectal cancer, and lays the groundwork for future studies targeting the tumor stroma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_1F424osEbVg90H21EOLACvtfcHk0lhOgOMBpHrgfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkt1Whsb8%253D&md5=7e69e1187b364d4c1ed43fef5d717c48</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4161%2Fcbt.6.11.4874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.6.11.4874%26sid%3Dliteratum%253Aachs%26aulast%3DNarra%26aufirst%3DK.%26aulast%3DMullins%26aufirst%3DS.%2BR.%26aulast%3DLee%26aufirst%3DH.%2BO.%26aulast%3DStrzemkowski-Brun%26aufirst%3DB.%26aulast%3DMagalong%26aufirst%3DK.%26aulast%3DChristiansen%26aufirst%3DV.%2BJ.%26aulast%3DMcKee%26aufirst%3DP.%2BA.%26aulast%3DEgleston%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DS.%2BJ.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26aulast%3DMeropol%26aufirst%3DN.%2BJ.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26atitle%3DPhase%2520II%2520trial%2520of%2520single%2520agent%2520Val-boroPro%2520%2528talabostat%2529%2520inhibiting%2520fibroblast%2520activation%2520protein%2520in%2520patients%2520with%2520metastatic%2520colorectal%2520cancer%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1691%26epage%3D1699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Eager, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senzer, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frenette, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uprichard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemunaitis, J.</span><span> </span><span class="NLM_article-title">Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=263&author=R.+M.+Eagerauthor=C.+C.+Cunninghamauthor=N.+N.+Senzerauthor=J.+Stephensonauthor=S.+P.+Anthonyauthor=S.+J.+O%E2%80%99Dayauthor=G.+Frenetteauthor=A.+C.+Pavlickauthor=B.+Jonesauthor=M.+Uprichardauthor=J.+Nemunaitis&title=Phase+II+assessment+of+talabostat+and+cisplatin+in+second-line+stage+IV+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEager%26aufirst%3DR.%2BM.%26aulast%3DCunningham%26aufirst%3DC.%2BC.%26aulast%3DSenzer%26aufirst%3DN.%2BN.%26aulast%3DStephenson%26aufirst%3DJ.%26aulast%3DAnthony%26aufirst%3DS.%2BP.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DFrenette%26aufirst%3DG.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DUprichard%26aufirst%3DM.%26aulast%3DNemunaitis%26aufirst%3DJ.%26atitle%3DPhase%2520II%2520assessment%2520of%2520talabostat%2520and%2520cisplatin%2520in%2520second-line%2520stage%2520IV%2520melanoma%26jtitle%3DBMC%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Eager, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senzer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raju, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uprichard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemunaitis, J.</span><span> </span><span class="NLM_article-title">Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">464</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1016%2Fj.clon.2009.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A280%3ADC%252BD1MvnslCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=464-472&author=R.+M.+Eagerauthor=C.+C.+Cunninghamauthor=N.+Senzerauthor=D.+A.+Richardsauthor=R.+N.+Rajuauthor=B.+Jonesauthor=M.+Uprichardauthor=J.+Nemunaitis&title=Phase+II+trial+of+talabostat+and+docetaxel+in+advanced+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer</span></div><div class="casAuthors">Eager R M; Cunningham C C; Senzer N; Richards D A; Raju R N; Jones B; Uprichard M; Nemunaitis J</div><div class="citationInfo"><span class="NLM_cas:title">Clinical oncology (Royal College of Radiologists (Great Britain))</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">464-72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  Currently available therapies do improve survival in advanced stage non-small cell lung cancer (NSCLC), but only to a limited degree.  Talabostat mesilate (PT-100) is an orally available amino boronic dipeptide that specifically inhibits dipeptidyl peptidases (including fibroblast activation protein) and enhances an immune response.  The aim of this study was to determine the efficacy and safety of talabostat in NSCLC patients.  MATERIALS AND METHODS:  A phase II trial was conducted to evaluate talabostat in combination with docetaxel in patients with advanced NSCLC after failure of previous platinum-based chemotherapy.  In total, 42 patients were enrolled.  RESULTS:  Talabostat was well tolerated.  Two patients achieved a partial response and one achieved a complete response.  CONCLUSION:  There was no evidence that talabostat enhanced the clinical activity of docetaxel in patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTzMVo_b7EzHWEEzDrymxmfW6udTcc2eazFZw-geMmsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvnslCjtw%253D%253D&md5=ad5ab6406f54c4a919563b02f0e0ac76</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.clon.2009.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clon.2009.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DEager%26aufirst%3DR.%2BM.%26aulast%3DCunningham%26aufirst%3DC.%2BC.%26aulast%3DSenzer%26aufirst%3DN.%26aulast%3DRichards%26aufirst%3DD.%2BA.%26aulast%3DRaju%26aufirst%3DR.%2BN.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DUprichard%26aufirst%3DM.%26aulast%3DNemunaitis%26aufirst%3DJ.%26atitle%3DPhase%2520II%2520trial%2520of%2520talabostat%2520and%2520docetaxel%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Oncol.%26date%3D2009%26volume%3D21%26spage%3D464%26epage%3D472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Walsh, M.; Krauss, A. C.; Davis, J. P.; Kim, S. Y.; Guimond, M.; Mackall, C. L.; Fry, T. J.</span><span> </span><span class="NLM_article-title">Dipeptidyl peptidase inhibition accelerates dendritic cell cross priming of tumor-reactive T cells resulting in regression of established tumors</span>. In <span class="NLM_conf-name">50<sup>th</sup> ASH Annual Meeting and Exposition</span>, <span class="NLM_conf-date">2008</span>, <div class="note"><p class="first last">Abstract 2579</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Walsh%2C+M.%3B+Krauss%2C+A.+C.%3B+Davis%2C+J.+P.%3B+Kim%2C+S.+Y.%3B+Guimond%2C+M.%3B+Mackall%2C+C.+L.%3B+Fry%2C+T.+J.+Dipeptidyl+peptidase+inhibition+accelerates+dendritic+cell+cross+priming+of+tumor-reactive+T+cells+resulting+in+regression+of+established+tumors.+In+50th+ASH+Annual+Meeting+and+Exposition%2C+2008%2C+Abstract+2579."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DM.%26atitle%3DDipeptidyl%2520peptidase%2520inhibition%2520accelerates%2520dendritic%2520cell%2520cross%2520priming%2520of%2520tumor-reactive%2520T%2520cells%2520resulting%2520in%2520regression%2520of%2520established%2520tumors" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Lankas, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiting, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beconi, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biftu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmondson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ippolito, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ok, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryor, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reigle, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N. A.</span><span> </span><span class="NLM_article-title">Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2988</span><span class="NLM_x">–</span> <span class="NLM_lpage">2994</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=2988-2994&author=G.+R.+Lankasauthor=B.+Leitingauthor=R.+S.+Royauthor=G.+J.+Eiermannauthor=M.+G.+Beconiauthor=T.+Biftuauthor=C.+C.+Chanauthor=S.+Edmondsonauthor=W.+P.+Feeneyauthor=H.+Heauthor=D.+E.+Ippolitoauthor=D.+Kimauthor=K.+A.+Lyonsauthor=H.+O.+Okauthor=R.+A.+Patelauthor=A.+N.+Petrovauthor=K.+A.+Pryorauthor=X.+Qianauthor=L.+Reigleauthor=A.+Woodsauthor=J.+K.+Wuauthor=D.+Zallerauthor=X.+Zhangauthor=L.+Zhuauthor=A.+E.+Weberauthor=N.+A.+Thornberry&title=Dipeptidyl+peptidase+IV+inhibition+for+the+treatment+of+type+2+diabetes%3A+potential+importance+of+selectivity+over+dipeptidyl+peptidases+8+and+9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLankas%26aufirst%3DG.%2BR.%26aulast%3DLeiting%26aufirst%3DB.%26aulast%3DRoy%26aufirst%3DR.%2BS.%26aulast%3DEiermann%26aufirst%3DG.%2BJ.%26aulast%3DBeconi%26aufirst%3DM.%2BG.%26aulast%3DBiftu%26aufirst%3DT.%26aulast%3DChan%26aufirst%3DC.%2BC.%26aulast%3DEdmondson%26aufirst%3DS.%26aulast%3DFeeney%26aufirst%3DW.%2BP.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DIppolito%26aufirst%3DD.%2BE.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DLyons%26aufirst%3DK.%2BA.%26aulast%3DOk%26aufirst%3DH.%2BO.%26aulast%3DPatel%26aufirst%3DR.%2BA.%26aulast%3DPetrov%26aufirst%3DA.%2BN.%26aulast%3DPryor%26aufirst%3DK.%2BA.%26aulast%3DQian%26aufirst%3DX.%26aulast%3DReigle%26aufirst%3DL.%26aulast%3DWoods%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DJ.%2BK.%26aulast%3DZaller%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26atitle%3DDipeptidyl%2520peptidase%2520IV%2520inhibition%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%253A%2520potential%2520importance%2520of%2520selectivity%2520over%2520dipeptidyl%2520peptidases%25208%2520and%25209%26jtitle%3DDiabetes%26date%3D2005%26volume%3D54%26spage%3D2988%26epage%3D2994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stafford, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaldor, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asakawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gwaltney, S. L.</span><span> </span><span class="NLM_article-title">Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2297</span><span class="NLM_x">–</span> <span class="NLM_lpage">2300</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070104l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2297-2300&author=J.+Fengauthor=Z.+Zhangauthor=M.+B.+Wallaceauthor=J.+A.+Staffordauthor=S.+W.+Kaldorauthor=D.+B.+Kasselauthor=M.+Navreauthor=L.+Shiauthor=R.+J.+Skeneauthor=T.+Asakawaauthor=K.+Takeuchiauthor=R.+Xuauthor=D.+R.+Webbauthor=S.+L.+Gwaltney&title=Discovery+of+alogliptin%3A+a+potent%2C+selective%2C+bioavailable%2C+and+efficacious+inhibitor+of+dipeptidyl+peptidase+IV"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm070104l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070104l%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWallace%26aufirst%3DM.%2BB.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26aulast%3DKaldor%26aufirst%3DS.%2BW.%26aulast%3DKassel%26aufirst%3DD.%2BB.%26aulast%3DNavre%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DAsakawa%26aufirst%3DT.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DWebb%26aufirst%3DD.%2BR.%26aulast%3DGwaltney%26aufirst%3DS.%2BL.%26atitle%3DDiscovery%2520of%2520alogliptin%253A%2520a%2520potent%252C%2520selective%252C%2520bioavailable%252C%2520and%2520efficacious%2520inhibitor%2520of%2520dipeptidyl%2520peptidase%2520IV%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2297%26epage%3D2300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Coutts, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krolikowski, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ksiazek, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span> </span><span class="NLM_article-title">Structure−activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2087</span><span class="NLM_x">–</span> <span class="NLM_lpage">2094</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm950732f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=2087-2094&author=S.+J.+Couttsauthor=T.+A.+Kellyauthor=R.+J.+Snowauthor=C.+A.+Kennedyauthor=R.+W.+Bartonauthor=J.+Adamsauthor=D.+A.+Krolikowskiauthor=D.+M.+Freemanauthor=S.+J.+Campbellauthor=J.+F.+Ksiazekauthor=W.+W.+Bachovchin&title=Structure%E2%88%92activity+relationships+of+boronic+acid+inhibitors+of+dipeptidyl+peptidase+IV.+1.+Variation+of+the+P2+position+of+Xaa-boroPro+dipeptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm950732f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950732f%26sid%3Dliteratum%253Aachs%26aulast%3DCoutts%26aufirst%3DS.%2BJ.%26aulast%3DKelly%26aufirst%3DT.%2BA.%26aulast%3DSnow%26aufirst%3DR.%2BJ.%26aulast%3DKennedy%26aufirst%3DC.%2BA.%26aulast%3DBarton%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DKrolikowski%26aufirst%3DD.%2BA.%26aulast%3DFreeman%26aufirst%3DD.%2BM.%26aulast%3DCampbell%26aufirst%3DS.%2BJ.%26aulast%3DKsiazek%26aufirst%3DJ.%2BF.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26atitle%3DStructure%25E2%2588%2592activity%2520relationships%2520of%2520boronic%2520acid%2520inhibitors%2520of%2520dipeptidyl%2520peptidase%2520IV.%25201.%2520Variation%2520of%2520the%2520P2%2520position%2520of%2520Xaa-boroPro%2520dipeptides%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D2087%26epage%3D2094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Cheng, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valianou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canutescu, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffe, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, L. M.</span><span> </span><span class="NLM_article-title">Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">351</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1158%2F1535-7163.MCT-05-0128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=15767544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Kgu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=351-360&author=J.+D.+Chengauthor=M.+Valianouauthor=A.+A.+Canutescuauthor=E.+K.+Jaffeauthor=H.+O.+Leeauthor=H.+Wangauthor=J.+H.+Laiauthor=W.+W.+Bachovchinauthor=L.+M.+Weiner&title=Abrogation+of+fibroblast+activation+protein+enzymatic+activity+attenuates+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth</span></div><div class="casAuthors">Cheng, Jonathan D.; Valianou, Matthildi; Canutescu, Adrian A.; Jaffe, Eileen K.; Lee, Hyung-Ok; Wang, Hao; Lai, Jack H.; Bachovchin, William W.; Weiner, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">351-360</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumor-assocd. fibroblasts are functionally and phenotypically distinct from normal fibroblasts that are not in the tumor microenvironment.  Fibroblast activation protein is a 95 kDa cell surface glycoprotein expressed by tumor stromal fibroblasts, and has been shown to have dipeptidyl peptidase and collagenase activity.  Site-directed mutagenesis at the catalytic site of fibroblast activation protein, Ser624 Ala624, resulted in an ∼100,000-fold loss of fibroblast activation protein dipeptidyl peptidase (DPP) activity.  HEK293 cells transfected with wild-type fibroblast activation protein, enzymic mutant (S624A) fibroblast activation protein, or vector alone, were inoculated s.c. into immunodeficient mouse to assess the contribution of fibroblast activation protein enzymic activity to tumor growth.  Overexpression of wild-type fibroblast activation protein showed growth potentiation and enhanced tumorigenicity compared with both fibroblast activation protein S624A and vector-transfected HEK293 xenografts.  HEK293 cells transfected with fibroblast activation protein S624A showed tumor growth rates and tumorigenicity potential similar only to vector-transfected HEK293.  In vivo assessment of fibroblast activation protein DPP activity of these tumors showed enhanced enzymic activity of wild-type fibroblast activation protein, with only baseline levels of fibroblast activation protein DPP activity in either fibroblast activation protein S624A or vector-only xenografts.  These results indicate that the enzymic activity of fibroblast activation protein is necessary for fibroblast activation protein-driven tumor growth in the HEK293 xenograft model system.  This establishes the proof-of-principle that the enzymic activity of fibroblast activation protein plays an important role in the promotion of tumor growth, and provides an attractive target for therapeutics designed to alter fibroblast activation protein-induced tumor growth by targeting its enzymic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJQ7ekEjT-O7Vg90H21EOLACvtfcHk0lhLwbBtsHNZvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Kgu7g%253D&md5=9ef5725b966bd47692ad130aecf56ba9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0128%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DValianou%26aufirst%3DM.%26aulast%3DCanutescu%26aufirst%3DA.%2BA.%26aulast%3DJaffe%26aufirst%3DE.%2BK.%26aulast%3DLee%26aufirst%3DH.%2BO.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLai%26aufirst%3DJ.%2BH.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26atitle%3DAbrogation%2520of%2520fibroblast%2520activation%2520protein%2520enzymatic%2520activity%2520attenuates%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2005%26volume%3D4%26spage%3D351%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Santos, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aziz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissil, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puré, E.</span><span> </span><span class="NLM_article-title">Targeting fibroblast activation protein inhibitor tumor stromagenesis and growth in mice</span> <span class="citation_source-journal">J. Clin. Invest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">3613</span><span class="NLM_x">–</span> <span class="NLM_lpage">3625</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2009&pages=3613-3625&author=A.+M.+Santosauthor=J.+Jungauthor=N.+Azizauthor=J.+L.+Kissilauthor=E.+Pur%C3%A9&title=Targeting+fibroblast+activation+protein+inhibitor+tumor+stromagenesis+and+growth+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DA.%2BM.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DAziz%26aufirst%3DN.%26aulast%3DKissil%26aufirst%3DJ.%2BL.%26aulast%3DPur%25C3%25A9%26aufirst%3DE.%26atitle%3DTargeting%2520fibroblast%2520activation%2520protein%2520inhibitor%2520tumor%2520stromagenesis%2520and%2520growth%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest%26date%3D2009%26volume%3D119%26spage%3D3613%26epage%3D3625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Jesson, M. I.; McLean, P. A.; Miller, G. T.; Adams, S.; Aubin, J.; Jones, B.</span><span> </span><span class="NLM_article-title">Immune mechanism of action of talabostat: a dipeptidyl peptidase targeted antitumor agent</span>. In <span class="NLM_conf-name">Proceedings of the 98th Annual Meeting of the American Association for Cancer Research</span>, <span class="NLM_conf-date">2007</span>, <div class="note"><p class="first last">Abstract 1894</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Jesson%2C+M.+I.%3B+McLean%2C+P.+A.%3B+Miller%2C+G.+T.%3B+Adams%2C+S.%3B+Aubin%2C+J.%3B+Jones%2C+B.+Immune+mechanism+of+action+of+talabostat%3A+a+dipeptidyl+peptidase+targeted+antitumor+agent.+In+Proceedings+of+the+98th+Annual+Meeting+of+the+American+Association+for+Cancer+Research%2C+2007%2C+Abstract+1894."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DJesson%26aufirst%3DM.%2BI.%26atitle%3DImmune%2520mechanism%2520of%2520action%2520of%2520talabostat%253A%2520a%2520dipeptidyl%2520peptidase%2520targeted%2520antitumor%2520agent" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Burkey, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassiepen, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trappe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juedes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. E.</span><span> </span><span class="NLM_article-title">Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited</span> <span class="citation_source-journal">Diabetes Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1057</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1111%2Fj.1463-1326.2008.00860.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=18422675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVeqsLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=1057-1061&author=B.+F.+Burkeyauthor=P.+K.+Hoffmannauthor=U.+Hassiepenauthor=J.+Trappeauthor=M.+Juedesauthor=J.+E.+Foley&title=Adverse+effects+of+dipeptidyl+peptidases+8+and+9+inhibition+in+rodents+revisited"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited</span></div><div class="casAuthors">Burkey, B. F.; Hoffmann, P. K.; Hassiepen, U.; Trappe, J.; Juedes, M.; Foley, J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1057-1061</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim: To evaluate the assocn. between inhibition of dipeptidyl peptidase (DPP)-8 and/or DPP-9 organ toxicities and mortality in rodents.  Research Design and Methods: The relative selectivity of the DPP-4 inhibitor, vildagliptin, was detd. by comparing its KI (concn. of compd. yielding 50% inhibition of the enzyme) values for inhibition of recombinant human DPP-4, DPP-8 and DPP-9 assessed in vitro.  In expts. performed in vivo, vildagliptin was administered by gavage for 13 wk, at doses up to 1500 mg/kg/day in CD-1 mice and at doses up to 900 mg/kg/day in Wistar rats.  Plasma concns. of vildagliptin were assessed at week 12, and toxicities previously ascribed to inhibition of DPP-8 and/or DPP-9 were assessed at week 13.  Results: The KI values for vildagliptin-induced inhibition of DPP-4, DPP-8 and DPP-9 were 3, 810 and 95 nM resp.  The mean plasma concn. 24 h after dose after 12-wk daily dosing with 1500 mg/kg/day in mice was 2279 nM.  The mean plasma drug level 24 h after dose after 12-wk daily dosing with 900 mg/kg/day in rats was 5729 nM.  These high doses maintained plasma drug levels well above the KI values for DPP-8 and DPP-9 throughout a 24-h period.  At these high doses, the toxicities of a selective DPP-8/DPP-9 inhibitor that were reported previously (100% mortality in mice, alopecia, thrombocytopenia, reticulocytopenia, enlarged lymph nodes, splenomegaly and 20% mortality in rats) were not obsd.  Conclusions: Inhibition of DPP-8 and DPP-9 per se does not lead to organ toxicities and mortality in rodents.  Thus, a mechanism other than DPP-8/DPP-9 inhibition likely underlies the toxicity previously reported to be assocd. with a selective DPP-8/DPP-9 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY8zdsP6qpIbVg90H21EOLACvtfcHk0lgLYYnxwRARQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVeqsLfJ&md5=0da6c4f34499ce1f558e28b877142519</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1463-1326.2008.00860.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1463-1326.2008.00860.x%26sid%3Dliteratum%253Aachs%26aulast%3DBurkey%26aufirst%3DB.%2BF.%26aulast%3DHoffmann%26aufirst%3DP.%2BK.%26aulast%3DHassiepen%26aufirst%3DU.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DJuedes%26aufirst%3DM.%26aulast%3DFoley%26aufirst%3DJ.%2BE.%26atitle%3DAdverse%2520effects%2520of%2520dipeptidyl%2520peptidases%25208%2520and%25209%2520inhibition%2520in%2520rodents%2520revisited%26jtitle%3DDiabetes%2520Obes.%2520Metab.%26date%3D2008%26volume%3D10%26spage%3D1057%26epage%3D1061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shy, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiaang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span> </span><span class="NLM_article-title">Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2009&pages=203-210&author=J.+Wuauthor=H.+Tangauthor=T.+Yehauthor=C.+Chenauthor=H.+Shyauthor=Y.+Chuauthor=C.+Chienauthor=T.+Tsaiauthor=Y.+Huangauthor=Y.+Huangauthor=C.+Huangauthor=H.+Tsengauthor=W.+Jiaangauthor=Y.+Chaoauthor=X.+Chen&title=Biochemistry%2C+pharmacokinetics%2C+and+toxicology+of+a+potent+and+selective+DPP8%2F9+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DYeh%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DShy%26aufirst%3DH.%26aulast%3DChu%26aufirst%3DY.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DTsai%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DTseng%26aufirst%3DH.%26aulast%3DJiaang%26aufirst%3DW.%26aulast%3DChao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DBiochemistry%252C%2520pharmacokinetics%252C%2520and%2520toxicology%2520of%2520a%2520potent%2520and%2520selective%2520DPP8%252F9%2520inhibitor%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2009%26volume%3D78%26spage%3D203%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Snow, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutts, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutheil, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, C. A.</span><span> </span><span class="NLM_article-title">Studies on proline boronic acid dipeptide inhibitors of dipeptidyl peptidase IV: identification of a cyclic species containing a B−N bond</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">10860</span><span class="NLM_x">–</span> <span class="NLM_lpage">10869</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00103a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=1994&pages=10860-10869&author=R.+J.+Snowauthor=W.+W.+Bachovchinauthor=R.+W.+Bartonauthor=S.+J.+Campbellauthor=S.+J.+Couttsauthor=D.+M.+Freemanauthor=W.+G.+Gutheilauthor=T.+A.+Kellyauthor=C.+A.+Kennedy&title=Studies+on+proline+boronic+acid+dipeptide+inhibitors+of+dipeptidyl+peptidase+IV%3A+identification+of+a+cyclic+species+containing+a+B%E2%88%92N+bond"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fja00103a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00103a002%26sid%3Dliteratum%253Aachs%26aulast%3DSnow%26aufirst%3DR.%2BJ.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26aulast%3DBarton%26aufirst%3DR.%2BW.%26aulast%3DCampbell%26aufirst%3DS.%2BJ.%26aulast%3DCoutts%26aufirst%3DS.%2BJ.%26aulast%3DFreeman%26aufirst%3DD.%2BM.%26aulast%3DGutheil%26aufirst%3DW.%2BG.%26aulast%3DKelly%26aufirst%3DT.%2BA.%26aulast%3DKennedy%26aufirst%3DC.%2BA.%26atitle%3DStudies%2520on%2520proline%2520boronic%2520acid%2520dipeptide%2520inhibitors%2520of%2520dipeptidyl%2520peptidase%2520IV%253A%2520identification%2520of%2520a%2520cyclic%2520species%2520containing%2520a%2520B%25E2%2588%2592N%2520bond%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1994%26volume%3D116%26spage%3D10860%26epage%3D10869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Bodor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, P.</span><span> </span><span class="NLM_article-title">Soft drug design: general principles and recent applications</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=10608921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltFWqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=58-101&author=N.+Bodorauthor=P.+Buchwald&title=Soft+drug+design%3A+general+principles+and+recent+applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Soft drug design: general principles and recent applications</span></div><div class="casAuthors">Bodor, Nicholas; Buchwald, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-101</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review with 208 refs.  Soft drug design represents a new approach aimed to design safer drugs with an increased therapeutic index by integrating metab. considerations into the drug design process.  Soft drugs are new therapeutic agents that undergo predictable metab. to inactive metabolites after exerting their therapeutic effect.  Hence, they are obtained by building into the mol., in addn. to the activity, the most desired way in which the mol. is to be deactivated and detoxified.  In an attempt to systematize and summarize the related work done in a no. of labs., including ours, the present review presents an overview of the general soft drug design principles and provides a variety of specific examples to illustrate the concepts.  A no. of already marketed drugs, such as esmolol, remifentanil, or loteprednol etabonate, resulted from the successful application of such design principles.  Many other promising drug candidates are currently under investigation in a variety of fields including possible soft antimicrobials, anticholinergics, corticosteroids, β-blockers, analgetics, ACE inhibitors, antiarrhythmics, and others.  Whenever possible, pharmacokinetic and pharmacodynamic properties are briefly summarized and compared to those of other compds. used in the same field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphV1vhXwTl8LVg90H21EOLACvtfcHk0lgLYYnxwRARQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltFWqsg%253D%253D&md5=e0ca493ba31d001e62a759be0fc4bcc8</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291098-1128%2528200001%252920%253A1%253C58%253A%253AAID-MED3%253E3.0.CO%253B2-X%26sid%3Dliteratum%253Aachs%26aulast%3DBodor%26aufirst%3DN.%26aulast%3DBuchwald%26aufirst%3DP.%26atitle%3DSoft%2520drug%2520design%253A%2520general%2520principles%2520and%2520recent%2520applications%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2000%26volume%3D20%26spage%3D58%26epage%3D101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Pao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, O. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, S.</span><span> </span><span class="NLM_article-title">In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=395-402&author=L.+Paoauthor=C.+Hsiongauthor=O.+Y.+Huauthor=J.+Wangauthor=S.+Ho&title=In+vitro+and+in+vivo+evaluation+of+the+metabolism+and+pharmacokinetics+of+sebacoyl+dinalbuphine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DL.%26aulast%3DHsiong%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DO.%2BY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%2520the%2520metabolism%2520and%2520pharmacokinetics%2520of%2520sebacoyl%2520dinalbuphine%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D395%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Kane, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2955</span><span class="NLM_x">–</span> <span class="NLM_lpage">2960</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1158%2F1078-0432.CCR-06-0170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=16707588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADC%252BD28Xks1Cisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=2955-2960&author=R.+C.+Kaneauthor=R.+T.+Farrellauthor=R.+Sridharaauthor=R.+Pazdur&title=United+States+Food+and+Drug+Administration+approval+summary%3A+bortezomib+for+the+treatment+of+progressive+multiple+myeloma+after+one+prior+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy</span></div><div class="casAuthors">Kane, Robert C.; Farrell, Ann T.; Sridhara, Rajeshwari; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2955-2960</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: On Mar. 25, 2005, bortezomib (Velcade for Injection; Millennium Pharmaceuticals, Inc., Cambridge, MA, and Johnson & Johnson Pharmaceutical Research & Development, L.L.C.) received regular approval from the U.S. Food and Drug Administration (U.S. FDA) for the treatment of multiple myeloma (MM) progressing after at least one prior therapy.  This approval was based on bortezomib's efficacy and safety which was shown in a single, large, comparative international open-label phase 3 trial that randomized 669 patients with MM previously treated with at least one systemic regimen to receive single-agent bortezomib or high-dose dexamethasone.  The FDA anal. of the trial data and bortezomib's regulatory development are summarized here.  Exptl. Design and Results: Following a preplanned interim anal. of time to disease progression (the primary end point), an independent data-monitoring committee advised the sponsor to halt the study and offer bortezomib to all dexamethasone-treated study patients.  Time to progression was significantly prolonged in the bortezomib treatment arm (median, 6.2 mo) compared with the dexamethasone arm (median, 3.5 mo; log-rank test, P < 0.0001; hazard ratio, 0.55; 95% confidence interval, 0.44-0.69).  Anal. of overall survival done on the interim database (with 20% of events) showed the superiority of bortezomib for patients (log-rank test, P < 0.05; hazard ratio, 0.57; 95% confidence interval, 0.40-0.81).  Using criteria from the European Group for Blood and Marrow Transplantation, the response rate (complete plus partial response) with bortezomib was also superior to dexamethasone (38% vs. 18%; P < 0.0001).  Adverse events on the bortezomib arm were similar to those previously obsd. in phase 2 studies; some notable adverse events included asthenia, peripheral neuropathy, thrombocytopenia, and neutropenia.  Conclusions: The U.S. FDA had earlier (May 2003) granted bortezomib accelerated approval for the treatment of patients with MM progressing after two prior therapies.  The results of the phase 3 trial and the FDA anal. of the data, along with the sponsor's completion of other postmarketing commitments, confirm bortezomib's benefit and support regular approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprCEo5n3GykbVg90H21EOLACvtfcHk0ljHutjsOd7DHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xks1Cisb8%253D&md5=943e7a08845337c9813ae01be5de83b3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0170%26sid%3Dliteratum%253Aachs%26aulast%3DKane%26aufirst%3DR.%2BC.%26aulast%3DFarrell%26aufirst%3DR.%2BT.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DUnited%2520States%2520Food%2520and%2520Drug%2520Administration%2520approval%2520summary%253A%2520bortezomib%2520for%2520the%2520treatment%2520of%2520progressive%2520multiple%2520myeloma%2520after%2520one%2520prior%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D2955%26epage%3D2960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Marguet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baggio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagtmann, N.</span><span> </span><span class="NLM_article-title">Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">6874</span><span class="NLM_x">–</span> <span class="NLM_lpage">6879</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=6874-6879&author=D.+Marguetauthor=L.+Baggioauthor=T.+Kobayashiauthor=A.+Bernardauthor=M.+Pierresauthor=P.+F.+Nielsenauthor=U.+Ribelauthor=T.+Watanabeauthor=D.+J.+Druckerauthor=N.+Wagtmann&title=Enhanced+insulin+secretion+and+improved+glucose+tolerance+in+mice+lacking+CD26"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarguet%26aufirst%3DD.%26aulast%3DBaggio%26aufirst%3DL.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DBernard%26aufirst%3DA.%26aulast%3DPierres%26aufirst%3DM.%26aulast%3DNielsen%26aufirst%3DP.%2BF.%26aulast%3DRibel%26aufirst%3DU.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DWagtmann%26aufirst%3DN.%26atitle%3DEnhanced%2520insulin%2520secretion%2520and%2520improved%2520glucose%2520tolerance%2520in%2520mice%2520lacking%2520CD26%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2000%26volume%3D97%26spage%3D6874%26epage%3D6879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 16 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">João
P. M. António, Lídia M. Gonçalves, Rita C. Guedes, Rui Moreira, <span class="NLM_string-name hlFld-ContribAuthor">Pedro M. P. Gois</span>. </span><span class="cited-content_cbyCitation_article-title">Diazaborines as New Inhibitors of Human Neutrophil Elastase. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (7)
                                     , 7418-7423. <a href="https://doi.org/10.1021/acsomega.8b00702" title="DOI URL">https://doi.org/10.1021/acsomega.8b00702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b00702%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDiazaborines%252Bas%252BNew%252BInhibitors%252Bof%252BHuman%252BNeutrophil%252BElastase%26aulast%3DAnt%25C3%25B3nio%26aufirst%3DJo%25C3%25A3o%2BP.%2BM.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D11042018%26date%3D20062018%26volume%3D3%26issue%3D7%26spage%3D7418%26epage%3D7423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sabrina  Touchet</span>, <span class="hlFld-ContribAuthor ">Aurélie  Macé</span>, <span class="hlFld-ContribAuthor ">Thierry  Roisnel</span>, <span class="hlFld-ContribAuthor ">François  Carreaux</span>, <span class="hlFld-ContribAuthor ">Alexandre  Bouillon</span>, and <span class="hlFld-ContribAuthor ">Bertrand  Carboni</span>  . </span><span class="cited-content_cbyCitation_article-title">[3,3]-Sigmatropic Rearrangement of Boronated Allylcyanates: A New Route to α-Aminoboronate Derivatives and Trisubstituted Tetrahydrofurans. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2013,</strong> <em>15 </em>
                                    (11)
                                     , 2712-2715. <a href="https://doi.org/10.1021/ol401016x" title="DOI URL">https://doi.org/10.1021/ol401016x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ol401016x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fol401016x%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3D%25255B3%25252C3%25255D-Sigmatropic%252BRearrangement%252Bof%252BBoronated%252BAllylcyanates%25253A%252BA%252BNew%252BRoute%252Bto%252B%2525CE%2525B1-Aminoboronate%252BDerivatives%252Band%252BTrisubstituted%252BTetrahydrofurans%26aulast%3DTouchet%26aufirst%3DSabrina%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D12042013%26date%3D21052013%26date%3D07062013%26volume%3D15%26issue%3D11%26spage%3D2712%26epage%3D2715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kun  Wen</span>, <span class="hlFld-ContribAuthor ">Han  Wang</span>, <span class="hlFld-ContribAuthor ">Jinbo  Chen</span>, <span class="hlFld-ContribAuthor ">He  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaodan  Cui</span>, <span class="hlFld-ContribAuthor ">Chao  Wei</span>, <span class="hlFld-ContribAuthor ">Erkang  Fan</span>, and <span class="hlFld-ContribAuthor ">Zhihua  Sun</span>  . </span><span class="cited-content_cbyCitation_article-title">Improving Carbene–Copper-Catalyzed Asymmetric Synthesis of α-Aminoboronic Esters Using Benzimidazole-Based Precursors. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2013,</strong> <em>78 </em>
                                    (7)
                                     , 3405-3409. <a href="https://doi.org/10.1021/jo4000477" title="DOI URL">https://doi.org/10.1021/jo4000477</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jo4000477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjo4000477%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DImproving%252BCarbene%2525E2%252580%252593Copper-Catalyzed%252BAsymmetric%252BSynthesis%252Bof%252B%2525CE%2525B1-Aminoboronic%252BEsters%252BUsing%252BBenzimidazole-Based%252BPrecursors%26aulast%3DWen%26aufirst%3DKun%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D15012013%26date%3D11032013%26date%3D05042013%26date%3D05032013%26volume%3D78%26issue%3D7%26spage%3D3405%26epage%3D3409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lawrence J.  Milo, Jr.</span>, <span class="hlFld-ContribAuthor ">Jack H.  Lai</span>, <span class="hlFld-ContribAuthor ">Wengen  Wu</span>, <span class="hlFld-ContribAuthor ">Yuxin  Liu</span>, <span class="hlFld-ContribAuthor ">Hlaing  Maw</span>, <span class="hlFld-ContribAuthor ">Youhua  Li</span>, <span class="hlFld-ContribAuthor ">Zhiping  Jin</span>, <span class="hlFld-ContribAuthor ">Ying  Shu</span>, <span class="hlFld-ContribAuthor ">Sarah E.  Poplawski</span>, <span class="hlFld-ContribAuthor ">Yong  Wu</span>, <span class="hlFld-ContribAuthor ">David G.  Sanford</span>, <span class="hlFld-ContribAuthor ">James L.  Sudmeier</span>, and <span class="hlFld-ContribAuthor ">William W.  Bachovchin</span>  . </span><span class="cited-content_cbyCitation_article-title">Chemical and Biological Evaluation of Dipeptidyl Boronic Acid Proteasome Inhibitors for Use in Prodrugs and Pro-Soft Drugs Targeting Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2011,</strong> <em>54 </em>
                                    (13)
                                     , 4365-4377. <a href="https://doi.org/10.1021/jm200460q" title="DOI URL">https://doi.org/10.1021/jm200460q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm200460q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm200460q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChemical%252Band%252BBiological%252BEvaluation%252Bof%252BDipeptidyl%252BBoronic%252BAcid%252BProteasome%252BInhibitors%252Bfor%252BUse%252Bin%252BProdrugs%252Band%252BPro-Soft%252BDrugs%252BTargeting%252BSolid%252BTumors%26aulast%3DMilo%26aufirst%3DLawrence%2BJ.%26date%3D2011%26date%3D2011%26date%3D2010%26date%3D23112010%26date%3D20062011%26date%3D14072011%26date%3D02062011%26volume%3D54%26issue%3D13%26spage%3D4365%26epage%3D4377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunyun  Wu</span>, <span class="hlFld-ContribAuthor ">Tiancong  Shi</span>, <span class="hlFld-ContribAuthor ">Jiqiu  Wang</span>, <span class="hlFld-ContribAuthor ">Rui  He</span>. </span><span class="cited-content_cbyCitation_article-title">Talabostat Alleviates Obesity and Associated Metabolic Dysfunction via Suppression of Macrophage‐Driven Adipose Inflammation. </span><span class="cited-content_cbyCitation_journal-name">Obesity</span><span> <strong>2021,</strong> <em>29 </em>
                                    (2)
                                     , 327-336. <a href="https://doi.org/10.1002/oby.23058" title="DOI URL">https://doi.org/10.1002/oby.23058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/oby.23058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Foby.23058%26sid%3Dliteratum%253Aachs%26jtitle%3DObesity%26atitle%3DTalabostat%252BAlleviates%252BObesity%252Band%252BAssociated%252BMetabolic%252BDysfunction%252Bvia%252BSuppression%252Bof%252BMacrophage%2525E2%252580%252590Driven%252BAdipose%252BInflammation%26aulast%3DWu%26aufirst%3DYunyun%26date%3D2021%26date%3D2020%26volume%3D29%26issue%3D2%26spage%3D327%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew G.  Leach</span>. </span><span class="cited-content_cbyCitation_article-title">Boron and covalent inhibition. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 135-201. <a href="https://doi.org/10.1016/bs.armc.2020.10.002" title="DOI URL">https://doi.org/10.1016/bs.armc.2020.10.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2020.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2020.10.002%26sid%3Dliteratum%253Aachs%26atitle%3DBoron%252Band%252Bcovalent%252Binhibition%26aulast%3DLeach%26aufirst%3DAndrew%2BG.%26date%3D2021%26spage%3D135%26epage%3D201%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica  Plescia</span>, <span class="hlFld-ContribAuthor ">Nicolas  Moitessier</span>. </span><span class="cited-content_cbyCitation_article-title">Design and discovery of boronic acid drugs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>195 </em>, 112270. <a href="https://doi.org/10.1016/j.ejmech.2020.112270" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112270</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112270%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bdiscovery%252Bof%252Bboronic%252Bacid%252Bdrugs%26aulast%3DPlescia%26aufirst%3DJessica%26date%3D2020%26volume%3D195%26spage%3D112270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel F.  Kawano</span>, <span class="hlFld-ContribAuthor ">Carlos H. T.  de Paula da Silva</span>, <span class="hlFld-ContribAuthor ">Carlton A.  Taft</span>. </span><span class="cited-content_cbyCitation_article-title">Design of Inhibitors of the Human Fibroblast Activation Protein α as a Strategy to Hinder Metastasis and Angiogenesis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 277-303. <a href="https://doi.org/10.1007/978-3-030-31403-3_11" title="DOI URL">https://doi.org/10.1007/978-3-030-31403-3_11</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-31403-3_11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-31403-3_11%26sid%3Dliteratum%253Aachs%26atitle%3DDesign%252Bof%252BInhibitors%252Bof%252Bthe%252BHuman%252BFibroblast%252BActivation%252BProtein%252B%2525CE%2525B1%252Bas%252Ba%252BStrategy%252Bto%252BHinder%252BMetastasis%252Band%252BAngiogenesis%26aulast%3DKawano%26aufirst%3DDaniel%2BF.%26date%3D2020%26date%3D2020%26spage%3D277%26epage%3D303%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DEmerging%252BResearch%252Bin%252BScience%252Band%252BEngineering%252BBased%252Bon%252BAdvanced%252BExperimental%252Band%252BComputational%252BStrategies%26aulast%3DLa%2BPorta%26aufirst%3DFelipe%2Bde%2BAlmeida%26date%3D2020%26volume%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harjeet S.  Soor</span>, <span class="hlFld-ContribAuthor ">Jonas  Hansen</span>, <span class="hlFld-ContribAuthor ">Diego B.  Diaz</span>, <span class="hlFld-ContribAuthor ">Solomon  Appavoo</span>, <span class="hlFld-ContribAuthor ">Andrei K.  Yudin</span>. </span><span class="cited-content_cbyCitation_article-title">Solid-phase synthesis of peptide β-aminoboronic acids. </span><span class="cited-content_cbyCitation_journal-name">Peptide Science</span><span> <strong>2019,</strong> <em>111 </em>
                                    (1)
                                     , e24072. <a href="https://doi.org/10.1002/pep2.24072" title="DOI URL">https://doi.org/10.1002/pep2.24072</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pep2.24072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpep2.24072%26sid%3Dliteratum%253Aachs%26jtitle%3DPeptide%2520Science%26atitle%3DSolid-phase%252Bsynthesis%252Bof%252Bpeptide%252B%2525CE%2525B2-aminoboronic%252Bacids%26aulast%3DSoor%26aufirst%3DHarjeet%2BS.%26date%3D2019%26date%3D2018%26volume%3D111%26issue%3D1%26spage%3De24072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brandon L.  Panaro</span>, <span class="hlFld-ContribAuthor ">Andrew L.  Coppage</span>, <span class="hlFld-ContribAuthor ">Jacqueline L.  Beaudry</span>, <span class="hlFld-ContribAuthor ">Elodie M.  Varin</span>, <span class="hlFld-ContribAuthor ">Kirandeep  Kaur</span>, <span class="hlFld-ContribAuthor ">Jack H.  Lai</span>, <span class="hlFld-ContribAuthor ">Wengen  Wu</span>, <span class="hlFld-ContribAuthor ">Yuxin  Liu</span>, <span class="hlFld-ContribAuthor ">William W.  Bachovchin</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Drucker</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblast activation protein is dispensable for control of glucose homeostasis and body weight in mice. </span><span class="cited-content_cbyCitation_journal-name">Molecular Metabolism</span><span> <strong>2019,</strong> <em>19 </em>, 65-74. <a href="https://doi.org/10.1016/j.molmet.2018.10.011" title="DOI URL">https://doi.org/10.1016/j.molmet.2018.10.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molmet.2018.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molmet.2018.10.011%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Metabolism%26atitle%3DFibroblast%252Bactivation%252Bprotein%252Bis%252Bdispensable%252Bfor%252Bcontrol%252Bof%252Bglucose%252Bhomeostasis%252Band%252Bbody%252Bweight%252Bin%252Bmice%26aulast%3DPanaro%26aufirst%3DBrandon%2BL.%26date%3D2019%26volume%3D19%26spage%3D65%26epage%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucienne  Juillerat-Jeanneret</span>, <span class="hlFld-ContribAuthor ">Petra  Tafelmeyer</span>, <span class="hlFld-ContribAuthor ">Dela  Golshayan</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Targets</span><span> <strong>2017,</strong> <em>21 </em>
                                    (10)
                                     , 977-991. <a href="https://doi.org/10.1080/14728222.2017.1370455" title="DOI URL">https://doi.org/10.1080/14728222.2017.1370455</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14728222.2017.1370455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14728222.2017.1370455%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Targets%26atitle%3DFibroblast%252Bactivation%252Bprotein-%2525CE%2525B1%252Bin%252Bfibrogenic%252Bdisorders%252Band%252Bcancer%25253A%252Bmore%252Bthan%252Ba%252Bprolyl-specific%252Bpeptidase%25253F%26aulast%3DJuillerat-Jeanneret%26aufirst%3DLucienne%26date%3D2017%26date%3D2017%26volume%3D21%26issue%3D10%26spage%3D977%26epage%3D991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bhumika D.  Patel</span>, <span class="hlFld-ContribAuthor ">Manjunath D.  Ghate</span>. </span><span class="cited-content_cbyCitation_article-title">Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>74 </em>, 574-605. <a href="https://doi.org/10.1016/j.ejmech.2013.12.038" title="DOI URL">https://doi.org/10.1016/j.ejmech.2013.12.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2013.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2013.12.038%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bapproaches%252Bto%252Bmedicinal%252Bchemistry%252Band%252Btherapeutic%252Bpotential%252Bof%252Bdipeptidyl%252Bpeptidase-4%252B%252528DPP-4%252529%252Binhibitors%26aulast%3DPatel%26aufirst%3DBhumika%2BD.%26date%3D2014%26volume%3D74%26spage%3D574%26epage%3D605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinbo  Chen</span>, <span class="hlFld-ContribAuthor ">Ling-yan  Chen</span>, <span class="hlFld-ContribAuthor ">Yue  Zheng</span>, <span class="hlFld-ContribAuthor ">Zhihua  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric synthesis of stable α-aminoboronic esters catalyzed by N-heterocylic carbene and copper(i) chloride. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2014,</strong> <em>4 </em>
                                    (40)
                                     , 21131. <a href="https://doi.org/10.1039/c4ra02229g" title="DOI URL">https://doi.org/10.1039/c4ra02229g</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c4ra02229g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc4ra02229g%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DAsymmetric%252Bsynthesis%252Bof%252Bstable%252B%2525CE%2525B1-aminoboronic%252Besters%252Bcatalyzed%252Bby%252BN-heterocylic%252Bcarbene%252Band%252Bcopper%252528i%252529%252Bchloride%26aulast%3DChen%26aufirst%3DJinbo%26date%3D2014%26volume%3D4%26issue%3D40%26spage%3D21131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicola  Micale</span>. </span><span class="cited-content_cbyCitation_article-title">Peptide-based boronates: How to achieve tissue specificity in anticancer therapy. </span><span class="cited-content_cbyCitation_journal-name">World Journal of Translational Medicine</span><span> <strong>2013,</strong> <em>2 </em>
                                    (3)
                                     , 32. <a href="https://doi.org/10.5528/wjtm.v2.i3.32" title="DOI URL">https://doi.org/10.5528/wjtm.v2.i3.32</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5528/wjtm.v2.i3.32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5528%2Fwjtm.v2.i3.32%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Journal%2520of%2520Translational%2520Medicine%26atitle%3DPeptide-based%252Bboronates%25253A%252BHow%252Bto%252Bachieve%252Btissue%252Bspecificity%252Bin%252Banticancer%252Btherapy%26aulast%3DMicale%26aufirst%3DNicola%26date%3D2013%26volume%3D2%26issue%3D3%26spage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Soft Drugs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2012,</strong>,, 77-258. <a href="https://doi.org/10.1002/9781118407738.ch5" title="DOI URL">https://doi.org/10.1002/9781118407738.ch5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118407738.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118407738.ch5%26sid%3Dliteratum%253Aachs%26atitle%3DSoft%252BDrugs%26date%3D2012%26date%3D2012%26spage%3D77%26epage%3D258%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DRetrometabolic%252BDrug%252BDesign%252Band%252BTargeting%26aulast%3DBodor%26aufirst%3DNicholas%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas  Kelly</span>, <span class="hlFld-ContribAuthor ">Yan  Huang</span>, <span class="hlFld-ContribAuthor ">Avis E.  Simms</span>, <span class="hlFld-ContribAuthor ">Anna  Mazur</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblast Activation Protein-α. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2012,</strong>,, 83-116. <a href="https://doi.org/10.1016/B978-0-12-394308-8.00003-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-394308-8.00003-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-394308-8.00003-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-394308-8.00003-0%26sid%3Dliteratum%253Aachs%26atitle%3DFibroblast%252BActivation%252BProtein-%2525CE%2525B1%26aulast%3DKelly%26aufirst%3DThomas%26date%3D2012%26spage%3D83%26epage%3D116%26pub%3DElsevier%26atitle%3DInternational%252BReview%252Bof%252BCell%252Band%252BMolecular%252BBiology%252BVolume%252B297%26date%3D2012%26volume%3D297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Cyclization Equilibrium of Val-boroPro</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Mechanism of pro-soft inhibition of DPPIV. Once the systemically inactive pro-soft drug encounters the DPPIV target enzyme, the N-terminal dipeptide is cleaved, releasing the linear dipeptide inhibitor in close proximity to its target enzyme. Any inhibitor that diffuses away, however, undergoes a pH-dependent cyclization, thereby attenuating potential systemic activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Pro-Soft Drugs Chg-Pro-Val-boroPro (<b>3</b>) and Phe-Pro-Ala-boroPro (<b>4</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. pH independence of smarter protease inhibitors in vitro. (A) Dipeptide boronic acid inhibitor <b>1</b> (circles) and its corresponding pro-soft drug <b>3</b> (squares). Open for pH 7.4 and closed for pH 2.0. (B) Dipeptide boronic acid inhibitor <b>2</b> (circles) and its corresponding pro-soft drug <b>4</b> (squares). Open for pH 7.4 and closed for pH 2.0.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0008.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Time course of pH dependent inactivation of a dipeptide boronic acid inhibitor following prodrug activation. IC<sub>50</sub> values for compound <b>5</b> were measured in vitro in the absence of chymotrypsin or following preincubation with chymotrypsin for varying periods of time.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0009.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pro-soft drug cleavage in vitro, monitoring for the dipeptide metabolite Chg-Pro. Activation of the pro-soft drug, <b>3</b>, in the presence (B), or absence (C) of purified DPPIV. Purified Chg-Pro was run as a reference (A).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0010.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Cleavage of <b>3</b> in wild-type (CD26<sup>+/+</sup>) and DPPIV knockout (CD26<sup>−/−</sup>) mice. Levels of intact <b>3</b> in serum from wild-type and DPPIV knockout mice previously given an intraperitoneal injection of the molecule were monitored via LC/MS (<i>n</i> = 3). The compound was administered 5 min prior to serum collection. *, <i>P</i> < 0.05. Error bars show mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0011.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparison of the in vivo performance of a dipeptide inhibitor (compound <b>1</b>) vs a pro-soft drug (compound <b>3</b>) in db/db mice. Serum DPPIV activity both 4 and 7 h following oral administration of 0.0025, 0.01, 0.025, or 0.05 mg/kg of <b>1</b> or <b>3</b> (<i>n</i> = 2, except for 0.5 mg/kg <b>1</b>, where <i>n</i> = 1) (A). Blood glucose levels following an oral glucose tolerance test in vehicle treated wild-type, vehicle treated db/db, and db/db mice administered 0.05 mg/kg <b>1</b> or <b>3</b> (<i>n</i> = 5) (B). The compounds were administered three hours prior to the oral glucose challenge. *, <i>P</i> < 0.05 and **, <i>P</i> < 0.001 versus diabetic control. Error bars show mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/medium/jm-2010-00972f_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0012.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Toxicity of the pro-soft drug (compound <b>3</b>) vs the dipeptide inhibitor (compound <b>1</b>) in rats. Percent survival after 24 h was assessed in Fischer rats following oral administration of 0.15, 0.5, or 1.5 mg/kg of <b>1</b> or <b>3</b> (<i>n</i> = 4).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-7/jm100972f/production/images/large/jm-2010-00972f_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100972f&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i32">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21683" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21683" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 28 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Adams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wantanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallner, B. P.</span><span> </span><span class="NLM_article-title">PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">5471</span><span class="NLM_x">–</span> <span class="NLM_lpage">5480</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=5471-5480&author=S.+Adamsauthor=G.+T.+Millerauthor=M.+I.+Jessonauthor=T.+Wantanabeauthor=B.+Jonesauthor=B.+P.+Wallner&title=PT-100%2C+a+small+molecule+dipeptidyl+peptidase+inhibitor%2C+has+potent+antitumor+effects+and+augments+antibody-mediated+cytotoxicity+via+a+novel+immune+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DG.%2BT.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DWantanabe%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DWallner%26aufirst%3DB.%2BP.%26atitle%3DPT-100%252C%2520a%2520small%2520molecule%2520dipeptidyl%2520peptidase%2520inhibitor%252C%2520has%2520potent%2520antitumor%2520effects%2520and%2520augments%2520antibody-mediated%2520cytotoxicity%2520via%2520a%2520novel%2520immune%2520mechanism%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D5471%26epage%3D5480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Kubota, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flentke, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stollar, B. D.</span><span> </span><span class="NLM_article-title">Involvement of dipeptidyl peptidase IV in an in vivo immune response</span> <span class="citation_source-journal">Clin. Exp. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1111%2Fj.1365-2249.1992.tb06931.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=1353423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADyaK3sXlsFCq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=192-197&author=T.+Kubotaauthor=G.+R.+Flentkeauthor=W.+W.+Bachovchinauthor=B.+D.+Stollar&title=Involvement+of+dipeptidyl+peptidase+IV+in+an+in+vivo+immune+response"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of dipeptidyl peptidase IV in an in vivo immune response</span></div><div class="casAuthors">Kubota, T.; Flentke, G. R.; Bachovchin, W. W.; Stollar, B. D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">192-7</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    </div><div class="casAbstract">Dipeptidyl peptidase IV (DP IV) is a serine protease that selectively cleaves X-Pro dipeptides from polypeptides and proteins.  Among blood cells, this enzyme occurs preferentially on the surface of CD4+ T cells and the amt. of enzyme activity increases with T cell activation.  In previous work, two potent and specific peptidyl-boronic acid inhibitors of DP IV, Ala-boroPro and Pro-boroPro, were synthesized and Pro-boroPro was shown to suppress antigen-specific proliferative responses of T cells in vitro.  This study tested the in vivo effects of these inhibitors.  The injection (s.c.) of Ala-boroPro or Pro-boroPro into BALB/c mice inhibited DP IV activity in serum and spleen cell suspensions.  Repeated injections of more than 10 μg of Ala-boroPro or Pro-boroPro at 12 h intervals maintained in vivo DP IV activity at less than 30% of the normal level.  Repeated injections of the inhibitors during the primary, secondary or tertiary immune response to bovine serum albumin (BSA) reduced anti-BSA antibody prodn.  Without inhibitor, immunization with BSA was followed by a temporary decrease in serum DP IV activity and then by enhanced serum enzyme activity after several days.  These results provide the first direct evidence that DP IV plays an important role in immune responses in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkpFlIa1M-1rVg90H21EOLACvtfcHk0ljkbQI2R5UDRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsFCq&md5=4eadb0f364cad70e7bdae9f37342495e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2249.1992.tb06931.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2249.1992.tb06931.x%26sid%3Dliteratum%253Aachs%26aulast%3DKubota%26aufirst%3DT.%26aulast%3DFlentke%26aufirst%3DG.%2BR.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26aulast%3DStollar%26aufirst%3DB.%2BD.%26atitle%3DInvolvement%2520of%2520dipeptidyl%2520peptidase%2520IV%2520in%2520an%2520in%2520vivo%2520immune%2520response%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D1992%26volume%3D89%26spage%3D192%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Kelly, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutts, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, R. J.</span><span> </span><span class="NLM_article-title">Immunosuppressive boronic acid dipeptides: correlation between conformation and activity</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">12637</span><span class="NLM_x">–</span> <span class="NLM_lpage">12638</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00079a074" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1993&pages=12637-12638&author=T.+A.+Kellyauthor=J.+Adamsauthor=W.+W.+Bachovchinauthor=R.+W.+Bartonauthor=S.+J.+Campbellauthor=S.+J.+Couttsauthor=C.+A.+Kennedyauthor=R.+J.+Snow&title=Immunosuppressive+boronic+acid+dipeptides%3A+correlation+between+conformation+and+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fja00079a074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00079a074%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DT.%2BA.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26aulast%3DBarton%26aufirst%3DR.%2BW.%26aulast%3DCampbell%26aufirst%3DS.%2BJ.%26aulast%3DCoutts%26aufirst%3DS.%2BJ.%26aulast%3DKennedy%26aufirst%3DC.%2BA.%26aulast%3DSnow%26aufirst%3DR.%2BJ.%26atitle%3DImmunosuppressive%2520boronic%2520acid%2520dipeptides%253A%2520correlation%2520between%2520conformation%2520and%2520activity%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1993%26volume%3D115%26spage%3D12637%26epage%3D12638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Mentlein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallwitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, W. E.</span><span> </span><span class="NLM_article-title">Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7−36)amide, peptide histidine methionine and is responsible for their degradation in human serum</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">214</span><span class="NLM_x">, </span> <span class="NLM_fpage">829</span><span class="NLM_x">–</span> <span class="NLM_lpage">835</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1111%2Fj.1432-1033.1993.tb17986.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=8100523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADyaK3sXks1elsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=1993&pages=829-835&author=R.+Mentleinauthor=B.+Gallwitzauthor=W.+E.+Schmidt&title=Dipeptidyl-peptidase+IV+hydrolyses+gastric+inhibitory+polypeptide%2C+glucagon-like+peptide-1%287%E2%88%9236%29amide%2C+peptide+histidine+methionine+and+is+responsible+for+their+degradation+in+human+serum"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Dipeptidyl-peptidase IV hydrolyzes gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum</span></div><div class="casAuthors">Mentlein, Rolf; Gallwitz, Baptist; Schmidt, Wolfgang E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">829-35</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    </div><div class="casAbstract">Peptides of the glucagon/VIP family share a considerable sequence similarity at their N-terminus.  They either start with Tyr-Ala, His-Ala or His-Ser which might be in part potential targets for dipeptidyl-peptidase IV, a highly specialized aminopeptidase removing dipeptides only from peptides with N-terminal penultimate proline or alanine.  GH-releasing factor(1-29)amide and gastric inhibitory peptide/glucose-dependent insulinotropic peptide (GIP) with terminal Tyr-Ala as well as glucagon-like peptide-1(7-36)amide/insulinotropin [GLP-1(7-36)amide] and peptide histidine methionine (PHM) with terminal His-Ala were hydrolyzed to their des-Xaa-Ala derivs. by dipeptidyl-peptidase IV purified from human placenta.  VIP with terminal His-Ser was not degraded by the peptidase.  The kinetics of the hydrolysis of GIP, GLP-1(7-36)amide and PHM were analyzed in detail.  For these peptides Km values of 4-34 μM and Vmax values of 0.6-3.8 μmol/min/mg protein were detd. for the purified peptidase which should allow their enzymic degrdn. also at physiol., nanomolar concns.  When human serum was incubated with GIP or GLP-1(7-36)amide the same fragments as with the purified dipeptidyl-peptidase IV, namely the des-Xaa-Ala peptides and Tyr-Ala in the case of GIP or His-Ala in the case of GLP-1(7-36)amide, were identified as the main degrdn. products of these peptide hormones.  Incorporation of inhibitors specific for dipeptidyl-peptidase IV, 1 mM Lys-pyrrolidide or 0.1 mM diprotin A (Ile-Pro-Ile), completely abolished the prodn. of these fragments by serum.  It is concluded that dipeptidyl-peptidase IV initiates the metab. of GIP and GLP-1(7-36)amide in human serum.  Since an intact N-terminus is obligate for the biol. activity of the members of the glucagon/VIP peptide family [e.g., GIP(3-42) is known to be inactive to release insulin in the presence of glucose as is intact GIP], dipeptidyl-peptidase-IV action inactivates these peptide hormones.  The relevance of this finding for their inactivation and their detn. by immunoassays is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaIzMbUUoh9LVg90H21EOLACvtfcHk0lgiT-uxED2i_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXks1elsLs%253D&md5=dd06411585d4e8bb42d5b093e895b900</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1993.tb17986.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1993.tb17986.x%26sid%3Dliteratum%253Aachs%26aulast%3DMentlein%26aufirst%3DR.%26aulast%3DGallwitz%26aufirst%3DB.%26aulast%3DSchmidt%26aufirst%3DW.%2BE.%26atitle%3DDipeptidyl-peptidase%2520IV%2520hydrolyses%2520gastric%2520inhibitory%2520polypeptide%252C%2520glucagon-like%2520peptide-1%25287%25E2%2588%259236%2529amide%252C%2520peptide%2520histidine%2520methionine%2520and%2520is%2520responsible%2520for%2520their%2520degradation%2520in%2520human%2520serum%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1993%26volume%3D214%26spage%3D829%26epage%3D835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Kieffer, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pederson, R. A.</span><span> </span><span class="NLM_article-title">Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">3585</span><span class="NLM_x">–</span> <span class="NLM_lpage">3596</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=1995&pages=3585-3596&author=T.+J.+Kiefferauthor=C.+H.+McIntoshauthor=R.+A.+Pederson&title=Degradation+of+glucose-dependent+insulinotropic+polypeptide+and+truncated+glucagon-like+peptide+1+in+vitro+and+in+vivo+by+dipeptidyl+peptidase+IV"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKieffer%26aufirst%3DT.%2BJ.%26aulast%3DMcIntosh%26aufirst%3DC.%2BH.%26aulast%3DPederson%26aufirst%3DR.%2BA.%26atitle%3DDegradation%2520of%2520glucose-dependent%2520insulinotropic%2520polypeptide%2520and%2520truncated%2520glucagon-like%2520peptide%25201%2520in%2520vitro%2520and%2520in%2520vivo%2520by%2520dipeptidyl%2520peptidase%2520IV%26jtitle%3DEndocrinology%26date%3D1995%26volume%3D136%26spage%3D3585%26epage%3D3596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Choy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, S.</span><span> </span><span class="NLM_article-title">Sitagliptin: a novel drug for the treatment of type 2 diabetes</span> <span class="citation_source-journal">Cardiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">271</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1097%2FCRD.0b013e318123f771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=17700385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A280%3ADC%252BD2svovFensw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=264-271&author=M.+Choyauthor=S.+Lam&title=Sitagliptin%3A+a+novel+drug+for+the+treatment+of+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Sitagliptin: a novel drug for the treatment of type 2 diabetes</span></div><div class="casAuthors">Choy Mary; Lam Sum</div><div class="citationInfo"><span class="NLM_cas:title">Cardiology in review</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">264-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type 2 diabetes mellitus is a common chronic disease that causes significant morbidity and mortality worldwide.  The primary goal of treatment is to target glycemic control by maintaining the glycosylated hemoglobin level near 6-7% without predisposing patients to hypoglycemia.  Diabetes results from a combination of increased hepatic glucose production, decreased insulin secretion from beta cells, and insulin resistance in the peripheral tissues.  Currently available antidiabetic agents work by different mechanisms to lower blood glucose levels.  Unfortunately, each of them has its tolerability and safety concerns that limit its use and dose titration.  Sitagliptin is the first antidiabetic agent from the class of dipeptidyl peptidase-4 enzyme inhibitors.  It increases the amount of circulating incretins, which stimulate insulin secretion and inhibit glucose production.  Sitagliptin was approved by the US Food and Drug Administration (FDA) for use with diet and exercise to improve glycemic control in adult patients with type 2 diabetes.  It can be used alone or in combination with metformin or a thiazolidinedione (pioglitazone or rosiglitazone) when treatment with either drug alone provides inadequate glucose control.  The usual adult dose is 100 mg once daily.  A dose of 25-50 mg once daily is recommended for patients with moderate-to-severe renal impairment.  In randomized, placebo-controlled trials that lasted for up to 6 months, sitagliptin lowered glycosylated hemoglobin levels by 0.5-0.8%.  In a 52-week clinical trial, sitagliptin was shown to be noninferior to glipizide as an add-on agent in patients inadequately controlled on metformin alone.  Sitagliptin was well tolerated with the most common side effects being gastrointestinal complaints (up to 16%), including abdominal pain, nausea and diarrhea; hypoglycemia and body weight gain occurred at similar rates compared with placebo.  Overall, sitagliptin provides a treatment option for patients with type 2 diabetes as a monotherapy, or as an adjunct to metformin or a thiazolidinedione when patients achieve inadequate glycemic control while on either of the agents.  It is also an alternative therapy for those patients who have contraindications or intolerability to other antidiabetic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQE6VB-Pf2cTq91pGlMMoT5fW6udTcc2eYtJGdgHNxxqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svovFensw%253D%253D&md5=f4f20ba2241dacf7e55c26d3c5cec66c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2FCRD.0b013e318123f771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCRD.0b013e318123f771%26sid%3Dliteratum%253Aachs%26aulast%3DChoy%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DS.%26atitle%3DSitagliptin%253A%2520a%2520novel%2520drug%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DCardiol.%2520Rev.%26date%3D2007%26volume%3D15%26spage%3D264%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Traynor, K.</span><span> </span><span class="NLM_article-title">FDA approves saxagliptin for type 2 diabetes</span> <span class="citation_source-journal">Am. J. Health Syst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1513</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=19710428" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2009&pages=1513&author=K.+Traynor&title=FDA+approves+saxagliptin+for+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTraynor%26aufirst%3DK.%26atitle%3DFDA%2520approves%2520saxagliptin%2520for%2520type%25202%2520diabetes%26jtitle%3DAm.%2520J.%2520Health%2520Syst.%26date%3D2009%26volume%3D66%26spage%3D1513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Croxtall, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keam, S. J.</span><span> </span><span class="NLM_article-title">Vildagliptin: a review of its use in the management of type 2 diabetes mellitus</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">2387</span><span class="NLM_x">–</span> <span class="NLM_lpage">2409</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=2387-2409&author=J.+D.+Croxtallauthor=S.+J.+Keam&title=Vildagliptin%3A+a+review+of+its+use+in+the+management+of+type+2+diabetes+mellitus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCroxtall%26aufirst%3DJ.%2BD.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DVildagliptin%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520management%2520of%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DDrugs%26date%3D2008%26volume%3D68%26spage%3D2387%26epage%3D2409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Horie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, M.</span><span> </span><span class="NLM_article-title">Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo</span> <span class="citation_source-journal">Trials</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=82&author=Y.+Horieauthor=N.+Hayashiauthor=K.+Dugiauthor=M.+Takeuchi&title=Design%2C+statistical+analysis+and+sample+size+calculation+of+a+phase+IIb%2FIII+study+of+linagliptin+versus+voglibose+and+placebo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHorie%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DN.%26aulast%3DDugi%26aufirst%3DK.%26aulast%3DTakeuchi%26aufirst%3DM.%26atitle%3DDesign%252C%2520statistical%2520analysis%2520and%2520sample%2520size%2520calculation%2520of%2520a%2520phase%2520IIb%252FIII%2520study%2520of%2520linagliptin%2520versus%2520voglibose%2520and%2520placebo%26jtitle%3DTrials%26date%3D2009%26volume%3D10%26spage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Pratley, R. E.</span><span> </span><span class="NLM_article-title">Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">512</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1517%2F14656560802694713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=19191685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVaiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=503-512&author=R.+E.+Pratley&title=Alogliptin%3A+a+new%2C+highly+selective+dipeptidyl+peptidase-4+inhibitor+for+the+treatment+of+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes</span></div><div class="casAuthors">Pratley, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">503-512</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Alogliptin is a potent, highly selective dipeptidyl peptidase-4 inhibitor now undergoing clin. testing to support a new drug application for the treatment of type 2 diabetes.  Objective: To provide an overview of the mechanism by which alogliptin reduces hyperglycemia and to summarize the pharmacol., efficacy and safety of the drug.  Methods: A Medline search was conducted and abstrs. and presentations from recent American Diabetes Assocn. and European Assocn. for the Study of Diabetes (EASD) meetings were reviewed.  The results of phase II and phase III human studies were evaluated for clin. efficacy, safety and tolerability in patients with type 2 diabetes.  Results/conclusions: Alogliptin is effective as a treatment for type 2 diabetes, either as monotherapy or in combination with metformin, thiazolidinediones, sulfonylureas and insulin.  It is well tolerated and has an excellent safety profile.  Addnl. studies are needed to evaluate the long-term safety and efficacy of alogliptin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVASaAmsEezrVg90H21EOLACvtfcHk0lgiT-uxED2i_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVaiurY%253D&md5=26b93655020e344a7a063a25aaed728d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1517%2F14656560802694713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560802694713%26sid%3Dliteratum%253Aachs%26aulast%3DPratley%26aufirst%3DR.%2BE.%26atitle%3DAlogliptin%253A%2520a%2520new%252C%2520highly%2520selective%2520dipeptidyl%2520peptidase-4%2520inhibitor%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2009%26volume%3D10%26spage%3D503%26epage%3D512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Connolly, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanford, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiluwal, A. K</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimare, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maw, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudmeier, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span> </span><span class="NLM_article-title">Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6005</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800390n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6005-13&author=B.+A.+Connollyauthor=D.+G.+Sanfordauthor=A.+K+Chiluwalauthor=S.+E.+Healeyauthor=D.+E.+Petersauthor=M.+T.+Dimareauthor=W.+Wuauthor=Y.+Liuauthor=H.+Mawauthor=Y.+Zhouauthor=Y.+Liauthor=Z.+Jinauthor=J.+L.+Sudmeierauthor=J.+H.+Laiauthor=W.+W.+Bachovchin&title=Dipeptide+boronic+acid+inhibitors+of+dipeptidyl+peptidase+IV%3A+determinants+of+potency+and+in+vivo+efficacy+and+safety"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm800390n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800390n%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DB.%2BA.%26aulast%3DSanford%26aufirst%3DD.%2BG.%26aulast%3DChiluwal%26aufirst%3DA.%2BK%26aulast%3DHealey%26aufirst%3DS.%2BE.%26aulast%3DPeters%26aufirst%3DD.%2BE.%26aulast%3DDimare%26aufirst%3DM.%2BT.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMaw%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DSudmeier%26aufirst%3DJ.%2BL.%26aulast%3DLai%26aufirst%3DJ.%2BH.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26atitle%3DDipeptide%2520boronic%2520acid%2520inhibitors%2520of%2520dipeptidyl%2520peptidase%2520IV%253A%2520determinants%2520of%2520potency%2520and%2520in%2520vivo%2520efficacy%2520and%2520safety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6005%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Narra, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullins, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strzemkowski-Brun, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magalong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiansen, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKee, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egleston, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meropol, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. D.</span><span> </span><span class="NLM_article-title">Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1691</span><span class="NLM_x">–</span> <span class="NLM_lpage">1699</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.4161%2Fcbt.6.11.4874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=18032930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkt1Whsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1691-1699&author=K.+Narraauthor=S.+R.+Mullinsauthor=H.+O.+Leeauthor=B.+Strzemkowski-Brunauthor=K.+Magalongauthor=V.+J.+Christiansenauthor=P.+A.+McKeeauthor=B.+Eglestonauthor=S.+J.+Cohenauthor=L.+M.+Weinerauthor=N.+J.+Meropolauthor=J.+D.+Cheng&title=Phase+II+trial+of+single+agent+Val-boroPro+%28talabostat%29+inhibiting+fibroblast+activation+protein+in+patients+with+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer</span></div><div class="casAuthors">Narra, Kalyani; Mullins, Stefanie R.; Lee, Hyung-Ok; Strzemkowski-Brun, Brenda; Magalong, Kimberly; Christiansen, Victoria J.; McKee, Patrick A.; Egleston, Brian; Cohen, Steven J.; Weiner, Louis M.; Meropol, Neal J.; Cheng, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1691-1699</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Purpose: Fibroblost Activation Protein (FAP) is a tumor fibroblast protease that has been shown to potentiate colorectal cancer growth.  The clin. impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clin. inhibitor of FAP enzymic activity, in a phase II study of patients with metastatic colorectal cancer.  Methods: Patients with metastatic colorectal cancer who had previously received systemic chemotherapies were treated with single agent Val-boroPro 200 μg p.o. BID continuously.  Eligibility included measurable disease, performance status of 0 to 2, and adequate organ function.  Lab. correlates evaluated the pharmacodynamic effects of Val-boroPro on FAP enzymic function in the peripheral blood.  Results: Twenty-eight patients (median age 62; 12 males, 16 females) were enrolled in this study.  There were no objective responses.  Six of 28 (21%) patients had stable disease for a median of 25 wk (range 11-38 wk).  Lab. anal. demonstrated significant, although incomplete inhibition of FAP enzymic activity in the peripheral blood.  Conclusion: This phase II trial of Val-boroPro demonstrated minimal clin. activity in patients with previously treated metastatic colorectal cancer.  However it provides the initial proof-of-concept that physiol. inhibition of FAP activity can be accomplished in patients with colorectal cancer, and lays the groundwork for future studies targeting the tumor stroma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_1F424osEbVg90H21EOLACvtfcHk0lin4XxCFQEjnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkt1Whsb8%253D&md5=7e69e1187b364d4c1ed43fef5d717c48</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4161%2Fcbt.6.11.4874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.6.11.4874%26sid%3Dliteratum%253Aachs%26aulast%3DNarra%26aufirst%3DK.%26aulast%3DMullins%26aufirst%3DS.%2BR.%26aulast%3DLee%26aufirst%3DH.%2BO.%26aulast%3DStrzemkowski-Brun%26aufirst%3DB.%26aulast%3DMagalong%26aufirst%3DK.%26aulast%3DChristiansen%26aufirst%3DV.%2BJ.%26aulast%3DMcKee%26aufirst%3DP.%2BA.%26aulast%3DEgleston%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DS.%2BJ.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26aulast%3DMeropol%26aufirst%3DN.%2BJ.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26atitle%3DPhase%2520II%2520trial%2520of%2520single%2520agent%2520Val-boroPro%2520%2528talabostat%2529%2520inhibiting%2520fibroblast%2520activation%2520protein%2520in%2520patients%2520with%2520metastatic%2520colorectal%2520cancer%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1691%26epage%3D1699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Eager, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senzer, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frenette, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uprichard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemunaitis, J.</span><span> </span><span class="NLM_article-title">Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=263&author=R.+M.+Eagerauthor=C.+C.+Cunninghamauthor=N.+N.+Senzerauthor=J.+Stephensonauthor=S.+P.+Anthonyauthor=S.+J.+O%E2%80%99Dayauthor=G.+Frenetteauthor=A.+C.+Pavlickauthor=B.+Jonesauthor=M.+Uprichardauthor=J.+Nemunaitis&title=Phase+II+assessment+of+talabostat+and+cisplatin+in+second-line+stage+IV+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEager%26aufirst%3DR.%2BM.%26aulast%3DCunningham%26aufirst%3DC.%2BC.%26aulast%3DSenzer%26aufirst%3DN.%2BN.%26aulast%3DStephenson%26aufirst%3DJ.%26aulast%3DAnthony%26aufirst%3DS.%2BP.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DFrenette%26aufirst%3DG.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DUprichard%26aufirst%3DM.%26aulast%3DNemunaitis%26aufirst%3DJ.%26atitle%3DPhase%2520II%2520assessment%2520of%2520talabostat%2520and%2520cisplatin%2520in%2520second-line%2520stage%2520IV%2520melanoma%26jtitle%3DBMC%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Eager, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senzer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raju, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uprichard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemunaitis, J.</span><span> </span><span class="NLM_article-title">Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">464</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1016%2Fj.clon.2009.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A280%3ADC%252BD1MvnslCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=464-472&author=R.+M.+Eagerauthor=C.+C.+Cunninghamauthor=N.+Senzerauthor=D.+A.+Richardsauthor=R.+N.+Rajuauthor=B.+Jonesauthor=M.+Uprichardauthor=J.+Nemunaitis&title=Phase+II+trial+of+talabostat+and+docetaxel+in+advanced+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer</span></div><div class="casAuthors">Eager R M; Cunningham C C; Senzer N; Richards D A; Raju R N; Jones B; Uprichard M; Nemunaitis J</div><div class="citationInfo"><span class="NLM_cas:title">Clinical oncology (Royal College of Radiologists (Great Britain))</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">464-72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  Currently available therapies do improve survival in advanced stage non-small cell lung cancer (NSCLC), but only to a limited degree.  Talabostat mesilate (PT-100) is an orally available amino boronic dipeptide that specifically inhibits dipeptidyl peptidases (including fibroblast activation protein) and enhances an immune response.  The aim of this study was to determine the efficacy and safety of talabostat in NSCLC patients.  MATERIALS AND METHODS:  A phase II trial was conducted to evaluate talabostat in combination with docetaxel in patients with advanced NSCLC after failure of previous platinum-based chemotherapy.  In total, 42 patients were enrolled.  RESULTS:  Talabostat was well tolerated.  Two patients achieved a partial response and one achieved a complete response.  CONCLUSION:  There was no evidence that talabostat enhanced the clinical activity of docetaxel in patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTzMVo_b7EzHWEEzDrymxmfW6udTcc2eYQc3RX_EeBx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvnslCjtw%253D%253D&md5=ad5ab6406f54c4a919563b02f0e0ac76</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.clon.2009.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clon.2009.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DEager%26aufirst%3DR.%2BM.%26aulast%3DCunningham%26aufirst%3DC.%2BC.%26aulast%3DSenzer%26aufirst%3DN.%26aulast%3DRichards%26aufirst%3DD.%2BA.%26aulast%3DRaju%26aufirst%3DR.%2BN.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DUprichard%26aufirst%3DM.%26aulast%3DNemunaitis%26aufirst%3DJ.%26atitle%3DPhase%2520II%2520trial%2520of%2520talabostat%2520and%2520docetaxel%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Oncol.%26date%3D2009%26volume%3D21%26spage%3D464%26epage%3D472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Walsh, M.; Krauss, A. C.; Davis, J. P.; Kim, S. Y.; Guimond, M.; Mackall, C. L.; Fry, T. J.</span><span> </span><span class="NLM_article-title">Dipeptidyl peptidase inhibition accelerates dendritic cell cross priming of tumor-reactive T cells resulting in regression of established tumors</span>. In <span class="NLM_conf-name">50<sup>th</sup> ASH Annual Meeting and Exposition</span>, <span class="NLM_conf-date">2008</span>, <div class="note"><p class="first last">Abstract 2579</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Walsh%2C+M.%3B+Krauss%2C+A.+C.%3B+Davis%2C+J.+P.%3B+Kim%2C+S.+Y.%3B+Guimond%2C+M.%3B+Mackall%2C+C.+L.%3B+Fry%2C+T.+J.+Dipeptidyl+peptidase+inhibition+accelerates+dendritic+cell+cross+priming+of+tumor-reactive+T+cells+resulting+in+regression+of+established+tumors.+In+50th+ASH+Annual+Meeting+and+Exposition%2C+2008%2C+Abstract+2579."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DM.%26atitle%3DDipeptidyl%2520peptidase%2520inhibition%2520accelerates%2520dendritic%2520cell%2520cross%2520priming%2520of%2520tumor-reactive%2520T%2520cells%2520resulting%2520in%2520regression%2520of%2520established%2520tumors" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Lankas, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiting, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beconi, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biftu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmondson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ippolito, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ok, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryor, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reigle, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N. A.</span><span> </span><span class="NLM_article-title">Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2988</span><span class="NLM_x">–</span> <span class="NLM_lpage">2994</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=2988-2994&author=G.+R.+Lankasauthor=B.+Leitingauthor=R.+S.+Royauthor=G.+J.+Eiermannauthor=M.+G.+Beconiauthor=T.+Biftuauthor=C.+C.+Chanauthor=S.+Edmondsonauthor=W.+P.+Feeneyauthor=H.+Heauthor=D.+E.+Ippolitoauthor=D.+Kimauthor=K.+A.+Lyonsauthor=H.+O.+Okauthor=R.+A.+Patelauthor=A.+N.+Petrovauthor=K.+A.+Pryorauthor=X.+Qianauthor=L.+Reigleauthor=A.+Woodsauthor=J.+K.+Wuauthor=D.+Zallerauthor=X.+Zhangauthor=L.+Zhuauthor=A.+E.+Weberauthor=N.+A.+Thornberry&title=Dipeptidyl+peptidase+IV+inhibition+for+the+treatment+of+type+2+diabetes%3A+potential+importance+of+selectivity+over+dipeptidyl+peptidases+8+and+9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLankas%26aufirst%3DG.%2BR.%26aulast%3DLeiting%26aufirst%3DB.%26aulast%3DRoy%26aufirst%3DR.%2BS.%26aulast%3DEiermann%26aufirst%3DG.%2BJ.%26aulast%3DBeconi%26aufirst%3DM.%2BG.%26aulast%3DBiftu%26aufirst%3DT.%26aulast%3DChan%26aufirst%3DC.%2BC.%26aulast%3DEdmondson%26aufirst%3DS.%26aulast%3DFeeney%26aufirst%3DW.%2BP.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DIppolito%26aufirst%3DD.%2BE.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DLyons%26aufirst%3DK.%2BA.%26aulast%3DOk%26aufirst%3DH.%2BO.%26aulast%3DPatel%26aufirst%3DR.%2BA.%26aulast%3DPetrov%26aufirst%3DA.%2BN.%26aulast%3DPryor%26aufirst%3DK.%2BA.%26aulast%3DQian%26aufirst%3DX.%26aulast%3DReigle%26aufirst%3DL.%26aulast%3DWoods%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DJ.%2BK.%26aulast%3DZaller%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26atitle%3DDipeptidyl%2520peptidase%2520IV%2520inhibition%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%253A%2520potential%2520importance%2520of%2520selectivity%2520over%2520dipeptidyl%2520peptidases%25208%2520and%25209%26jtitle%3DDiabetes%26date%3D2005%26volume%3D54%26spage%3D2988%26epage%3D2994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stafford, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaldor, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asakawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gwaltney, S. L.</span><span> </span><span class="NLM_article-title">Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2297</span><span class="NLM_x">–</span> <span class="NLM_lpage">2300</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070104l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2297-2300&author=J.+Fengauthor=Z.+Zhangauthor=M.+B.+Wallaceauthor=J.+A.+Staffordauthor=S.+W.+Kaldorauthor=D.+B.+Kasselauthor=M.+Navreauthor=L.+Shiauthor=R.+J.+Skeneauthor=T.+Asakawaauthor=K.+Takeuchiauthor=R.+Xuauthor=D.+R.+Webbauthor=S.+L.+Gwaltney&title=Discovery+of+alogliptin%3A+a+potent%2C+selective%2C+bioavailable%2C+and+efficacious+inhibitor+of+dipeptidyl+peptidase+IV"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm070104l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070104l%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWallace%26aufirst%3DM.%2BB.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26aulast%3DKaldor%26aufirst%3DS.%2BW.%26aulast%3DKassel%26aufirst%3DD.%2BB.%26aulast%3DNavre%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DAsakawa%26aufirst%3DT.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DWebb%26aufirst%3DD.%2BR.%26aulast%3DGwaltney%26aufirst%3DS.%2BL.%26atitle%3DDiscovery%2520of%2520alogliptin%253A%2520a%2520potent%252C%2520selective%252C%2520bioavailable%252C%2520and%2520efficacious%2520inhibitor%2520of%2520dipeptidyl%2520peptidase%2520IV%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2297%26epage%3D2300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Coutts, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krolikowski, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ksiazek, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span> </span><span class="NLM_article-title">Structure−activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2087</span><span class="NLM_x">–</span> <span class="NLM_lpage">2094</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm950732f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=2087-2094&author=S.+J.+Couttsauthor=T.+A.+Kellyauthor=R.+J.+Snowauthor=C.+A.+Kennedyauthor=R.+W.+Bartonauthor=J.+Adamsauthor=D.+A.+Krolikowskiauthor=D.+M.+Freemanauthor=S.+J.+Campbellauthor=J.+F.+Ksiazekauthor=W.+W.+Bachovchin&title=Structure%E2%88%92activity+relationships+of+boronic+acid+inhibitors+of+dipeptidyl+peptidase+IV.+1.+Variation+of+the+P2+position+of+Xaa-boroPro+dipeptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm950732f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950732f%26sid%3Dliteratum%253Aachs%26aulast%3DCoutts%26aufirst%3DS.%2BJ.%26aulast%3DKelly%26aufirst%3DT.%2BA.%26aulast%3DSnow%26aufirst%3DR.%2BJ.%26aulast%3DKennedy%26aufirst%3DC.%2BA.%26aulast%3DBarton%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DKrolikowski%26aufirst%3DD.%2BA.%26aulast%3DFreeman%26aufirst%3DD.%2BM.%26aulast%3DCampbell%26aufirst%3DS.%2BJ.%26aulast%3DKsiazek%26aufirst%3DJ.%2BF.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26atitle%3DStructure%25E2%2588%2592activity%2520relationships%2520of%2520boronic%2520acid%2520inhibitors%2520of%2520dipeptidyl%2520peptidase%2520IV.%25201.%2520Variation%2520of%2520the%2520P2%2520position%2520of%2520Xaa-boroPro%2520dipeptides%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D2087%26epage%3D2094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Cheng, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valianou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canutescu, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffe, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, L. M.</span><span> </span><span class="NLM_article-title">Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">351</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1158%2F1535-7163.MCT-05-0128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=15767544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Kgu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=351-360&author=J.+D.+Chengauthor=M.+Valianouauthor=A.+A.+Canutescuauthor=E.+K.+Jaffeauthor=H.+O.+Leeauthor=H.+Wangauthor=J.+H.+Laiauthor=W.+W.+Bachovchinauthor=L.+M.+Weiner&title=Abrogation+of+fibroblast+activation+protein+enzymatic+activity+attenuates+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth</span></div><div class="casAuthors">Cheng, Jonathan D.; Valianou, Matthildi; Canutescu, Adrian A.; Jaffe, Eileen K.; Lee, Hyung-Ok; Wang, Hao; Lai, Jack H.; Bachovchin, William W.; Weiner, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">351-360</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumor-assocd. fibroblasts are functionally and phenotypically distinct from normal fibroblasts that are not in the tumor microenvironment.  Fibroblast activation protein is a 95 kDa cell surface glycoprotein expressed by tumor stromal fibroblasts, and has been shown to have dipeptidyl peptidase and collagenase activity.  Site-directed mutagenesis at the catalytic site of fibroblast activation protein, Ser624 Ala624, resulted in an ∼100,000-fold loss of fibroblast activation protein dipeptidyl peptidase (DPP) activity.  HEK293 cells transfected with wild-type fibroblast activation protein, enzymic mutant (S624A) fibroblast activation protein, or vector alone, were inoculated s.c. into immunodeficient mouse to assess the contribution of fibroblast activation protein enzymic activity to tumor growth.  Overexpression of wild-type fibroblast activation protein showed growth potentiation and enhanced tumorigenicity compared with both fibroblast activation protein S624A and vector-transfected HEK293 xenografts.  HEK293 cells transfected with fibroblast activation protein S624A showed tumor growth rates and tumorigenicity potential similar only to vector-transfected HEK293.  In vivo assessment of fibroblast activation protein DPP activity of these tumors showed enhanced enzymic activity of wild-type fibroblast activation protein, with only baseline levels of fibroblast activation protein DPP activity in either fibroblast activation protein S624A or vector-only xenografts.  These results indicate that the enzymic activity of fibroblast activation protein is necessary for fibroblast activation protein-driven tumor growth in the HEK293 xenograft model system.  This establishes the proof-of-principle that the enzymic activity of fibroblast activation protein plays an important role in the promotion of tumor growth, and provides an attractive target for therapeutics designed to alter fibroblast activation protein-induced tumor growth by targeting its enzymic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJQ7ekEjT-O7Vg90H21EOLACvtfcHk0lg01KszWc5WFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Kgu7g%253D&md5=9ef5725b966bd47692ad130aecf56ba9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0128%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DValianou%26aufirst%3DM.%26aulast%3DCanutescu%26aufirst%3DA.%2BA.%26aulast%3DJaffe%26aufirst%3DE.%2BK.%26aulast%3DLee%26aufirst%3DH.%2BO.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLai%26aufirst%3DJ.%2BH.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26atitle%3DAbrogation%2520of%2520fibroblast%2520activation%2520protein%2520enzymatic%2520activity%2520attenuates%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2005%26volume%3D4%26spage%3D351%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Santos, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aziz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissil, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puré, E.</span><span> </span><span class="NLM_article-title">Targeting fibroblast activation protein inhibitor tumor stromagenesis and growth in mice</span> <span class="citation_source-journal">J. Clin. Invest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">3613</span><span class="NLM_x">–</span> <span class="NLM_lpage">3625</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2009&pages=3613-3625&author=A.+M.+Santosauthor=J.+Jungauthor=N.+Azizauthor=J.+L.+Kissilauthor=E.+Pur%C3%A9&title=Targeting+fibroblast+activation+protein+inhibitor+tumor+stromagenesis+and+growth+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DA.%2BM.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DAziz%26aufirst%3DN.%26aulast%3DKissil%26aufirst%3DJ.%2BL.%26aulast%3DPur%25C3%25A9%26aufirst%3DE.%26atitle%3DTargeting%2520fibroblast%2520activation%2520protein%2520inhibitor%2520tumor%2520stromagenesis%2520and%2520growth%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest%26date%3D2009%26volume%3D119%26spage%3D3613%26epage%3D3625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Jesson, M. I.; McLean, P. A.; Miller, G. T.; Adams, S.; Aubin, J.; Jones, B.</span><span> </span><span class="NLM_article-title">Immune mechanism of action of talabostat: a dipeptidyl peptidase targeted antitumor agent</span>. In <span class="NLM_conf-name">Proceedings of the 98th Annual Meeting of the American Association for Cancer Research</span>, <span class="NLM_conf-date">2007</span>, <div class="note"><p class="first last">Abstract 1894</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Jesson%2C+M.+I.%3B+McLean%2C+P.+A.%3B+Miller%2C+G.+T.%3B+Adams%2C+S.%3B+Aubin%2C+J.%3B+Jones%2C+B.+Immune+mechanism+of+action+of+talabostat%3A+a+dipeptidyl+peptidase+targeted+antitumor+agent.+In+Proceedings+of+the+98th+Annual+Meeting+of+the+American+Association+for+Cancer+Research%2C+2007%2C+Abstract+1894."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DJesson%26aufirst%3DM.%2BI.%26atitle%3DImmune%2520mechanism%2520of%2520action%2520of%2520talabostat%253A%2520a%2520dipeptidyl%2520peptidase%2520targeted%2520antitumor%2520agent" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Burkey, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassiepen, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trappe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juedes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. E.</span><span> </span><span class="NLM_article-title">Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited</span> <span class="citation_source-journal">Diabetes Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1057</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1111%2Fj.1463-1326.2008.00860.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=18422675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVeqsLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=1057-1061&author=B.+F.+Burkeyauthor=P.+K.+Hoffmannauthor=U.+Hassiepenauthor=J.+Trappeauthor=M.+Juedesauthor=J.+E.+Foley&title=Adverse+effects+of+dipeptidyl+peptidases+8+and+9+inhibition+in+rodents+revisited"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited</span></div><div class="casAuthors">Burkey, B. F.; Hoffmann, P. K.; Hassiepen, U.; Trappe, J.; Juedes, M.; Foley, J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1057-1061</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim: To evaluate the assocn. between inhibition of dipeptidyl peptidase (DPP)-8 and/or DPP-9 organ toxicities and mortality in rodents.  Research Design and Methods: The relative selectivity of the DPP-4 inhibitor, vildagliptin, was detd. by comparing its KI (concn. of compd. yielding 50% inhibition of the enzyme) values for inhibition of recombinant human DPP-4, DPP-8 and DPP-9 assessed in vitro.  In expts. performed in vivo, vildagliptin was administered by gavage for 13 wk, at doses up to 1500 mg/kg/day in CD-1 mice and at doses up to 900 mg/kg/day in Wistar rats.  Plasma concns. of vildagliptin were assessed at week 12, and toxicities previously ascribed to inhibition of DPP-8 and/or DPP-9 were assessed at week 13.  Results: The KI values for vildagliptin-induced inhibition of DPP-4, DPP-8 and DPP-9 were 3, 810 and 95 nM resp.  The mean plasma concn. 24 h after dose after 12-wk daily dosing with 1500 mg/kg/day in mice was 2279 nM.  The mean plasma drug level 24 h after dose after 12-wk daily dosing with 900 mg/kg/day in rats was 5729 nM.  These high doses maintained plasma drug levels well above the KI values for DPP-8 and DPP-9 throughout a 24-h period.  At these high doses, the toxicities of a selective DPP-8/DPP-9 inhibitor that were reported previously (100% mortality in mice, alopecia, thrombocytopenia, reticulocytopenia, enlarged lymph nodes, splenomegaly and 20% mortality in rats) were not obsd.  Conclusions: Inhibition of DPP-8 and DPP-9 per se does not lead to organ toxicities and mortality in rodents.  Thus, a mechanism other than DPP-8/DPP-9 inhibition likely underlies the toxicity previously reported to be assocd. with a selective DPP-8/DPP-9 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY8zdsP6qpIbVg90H21EOLACvtfcHk0lg01KszWc5WFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVeqsLfJ&md5=0da6c4f34499ce1f558e28b877142519</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1463-1326.2008.00860.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1463-1326.2008.00860.x%26sid%3Dliteratum%253Aachs%26aulast%3DBurkey%26aufirst%3DB.%2BF.%26aulast%3DHoffmann%26aufirst%3DP.%2BK.%26aulast%3DHassiepen%26aufirst%3DU.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DJuedes%26aufirst%3DM.%26aulast%3DFoley%26aufirst%3DJ.%2BE.%26atitle%3DAdverse%2520effects%2520of%2520dipeptidyl%2520peptidases%25208%2520and%25209%2520inhibition%2520in%2520rodents%2520revisited%26jtitle%3DDiabetes%2520Obes.%2520Metab.%26date%3D2008%26volume%3D10%26spage%3D1057%26epage%3D1061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shy, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiaang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span> </span><span class="NLM_article-title">Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2009&pages=203-210&author=J.+Wuauthor=H.+Tangauthor=T.+Yehauthor=C.+Chenauthor=H.+Shyauthor=Y.+Chuauthor=C.+Chienauthor=T.+Tsaiauthor=Y.+Huangauthor=Y.+Huangauthor=C.+Huangauthor=H.+Tsengauthor=W.+Jiaangauthor=Y.+Chaoauthor=X.+Chen&title=Biochemistry%2C+pharmacokinetics%2C+and+toxicology+of+a+potent+and+selective+DPP8%2F9+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DYeh%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DShy%26aufirst%3DH.%26aulast%3DChu%26aufirst%3DY.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DTsai%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DTseng%26aufirst%3DH.%26aulast%3DJiaang%26aufirst%3DW.%26aulast%3DChao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DBiochemistry%252C%2520pharmacokinetics%252C%2520and%2520toxicology%2520of%2520a%2520potent%2520and%2520selective%2520DPP8%252F9%2520inhibitor%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2009%26volume%3D78%26spage%3D203%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Snow, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutts, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutheil, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, C. A.</span><span> </span><span class="NLM_article-title">Studies on proline boronic acid dipeptide inhibitors of dipeptidyl peptidase IV: identification of a cyclic species containing a B−N bond</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">10860</span><span class="NLM_x">–</span> <span class="NLM_lpage">10869</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00103a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=1994&pages=10860-10869&author=R.+J.+Snowauthor=W.+W.+Bachovchinauthor=R.+W.+Bartonauthor=S.+J.+Campbellauthor=S.+J.+Couttsauthor=D.+M.+Freemanauthor=W.+G.+Gutheilauthor=T.+A.+Kellyauthor=C.+A.+Kennedy&title=Studies+on+proline+boronic+acid+dipeptide+inhibitors+of+dipeptidyl+peptidase+IV%3A+identification+of+a+cyclic+species+containing+a+B%E2%88%92N+bond"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fja00103a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00103a002%26sid%3Dliteratum%253Aachs%26aulast%3DSnow%26aufirst%3DR.%2BJ.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26aulast%3DBarton%26aufirst%3DR.%2BW.%26aulast%3DCampbell%26aufirst%3DS.%2BJ.%26aulast%3DCoutts%26aufirst%3DS.%2BJ.%26aulast%3DFreeman%26aufirst%3DD.%2BM.%26aulast%3DGutheil%26aufirst%3DW.%2BG.%26aulast%3DKelly%26aufirst%3DT.%2BA.%26aulast%3DKennedy%26aufirst%3DC.%2BA.%26atitle%3DStudies%2520on%2520proline%2520boronic%2520acid%2520dipeptide%2520inhibitors%2520of%2520dipeptidyl%2520peptidase%2520IV%253A%2520identification%2520of%2520a%2520cyclic%2520species%2520containing%2520a%2520B%25E2%2588%2592N%2520bond%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1994%26volume%3D116%26spage%3D10860%26epage%3D10869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Bodor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, P.</span><span> </span><span class="NLM_article-title">Soft drug design: general principles and recent applications</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=10608921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltFWqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=58-101&author=N.+Bodorauthor=P.+Buchwald&title=Soft+drug+design%3A+general+principles+and+recent+applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Soft drug design: general principles and recent applications</span></div><div class="casAuthors">Bodor, Nicholas; Buchwald, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-101</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review with 208 refs.  Soft drug design represents a new approach aimed to design safer drugs with an increased therapeutic index by integrating metab. considerations into the drug design process.  Soft drugs are new therapeutic agents that undergo predictable metab. to inactive metabolites after exerting their therapeutic effect.  Hence, they are obtained by building into the mol., in addn. to the activity, the most desired way in which the mol. is to be deactivated and detoxified.  In an attempt to systematize and summarize the related work done in a no. of labs., including ours, the present review presents an overview of the general soft drug design principles and provides a variety of specific examples to illustrate the concepts.  A no. of already marketed drugs, such as esmolol, remifentanil, or loteprednol etabonate, resulted from the successful application of such design principles.  Many other promising drug candidates are currently under investigation in a variety of fields including possible soft antimicrobials, anticholinergics, corticosteroids, β-blockers, analgetics, ACE inhibitors, antiarrhythmics, and others.  Whenever possible, pharmacokinetic and pharmacodynamic properties are briefly summarized and compared to those of other compds. used in the same field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphV1vhXwTl8LVg90H21EOLACvtfcHk0lgcyjIsmfBWWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltFWqsg%253D%253D&md5=e0ca493ba31d001e62a759be0fc4bcc8</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291098-1128%2528200001%252920%253A1%253C58%253A%253AAID-MED3%253E3.0.CO%253B2-X%26sid%3Dliteratum%253Aachs%26aulast%3DBodor%26aufirst%3DN.%26aulast%3DBuchwald%26aufirst%3DP.%26atitle%3DSoft%2520drug%2520design%253A%2520general%2520principles%2520and%2520recent%2520applications%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2000%26volume%3D20%26spage%3D58%26epage%3D101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Pao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, O. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, S.</span><span> </span><span class="NLM_article-title">In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=395-402&author=L.+Paoauthor=C.+Hsiongauthor=O.+Y.+Huauthor=J.+Wangauthor=S.+Ho&title=In+vitro+and+in+vivo+evaluation+of+the+metabolism+and+pharmacokinetics+of+sebacoyl+dinalbuphine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DL.%26aulast%3DHsiong%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DO.%2BY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%2520the%2520metabolism%2520and%2520pharmacokinetics%2520of%2520sebacoyl%2520dinalbuphine%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D395%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Kane, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2955</span><span class="NLM_x">–</span> <span class="NLM_lpage">2960</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm100972f&amp;key=10.1158%2F1078-0432.CCR-06-0170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm100972f&amp;key=16707588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm100972f&amp;key=1%3ACAS%3A528%3ADC%252BD28Xks1Cisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=2955-2960&author=R.+C.+Kaneauthor=R.+T.+Farrellauthor=R.+Sridharaauthor=R.+Pazdur&title=United+States+Food+and+Drug+Administration+approval+summary%3A+bortezomib+for+the+treatment+of+progressive+multiple+myeloma+after+one+prior+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy</span></div><div class="casAuthors">Kane, Robert C.; Farrell, Ann T.; Sridhara, Rajeshwari; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2955-2960</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: On Mar. 25, 2005, bortezomib (Velcade for Injection; Millennium Pharmaceuticals, Inc., Cambridge, MA, and Johnson & Johnson Pharmaceutical Research & Development, L.L.C.) received regular approval from the U.S. Food and Drug Administration (U.S. FDA) for the treatment of multiple myeloma (MM) progressing after at least one prior therapy.  This approval was based on bortezomib's efficacy and safety which was shown in a single, large, comparative international open-label phase 3 trial that randomized 669 patients with MM previously treated with at least one systemic regimen to receive single-agent bortezomib or high-dose dexamethasone.  The FDA anal. of the trial data and bortezomib's regulatory development are summarized here.  Exptl. Design and Results: Following a preplanned interim anal. of time to disease progression (the primary end point), an independent data-monitoring committee advised the sponsor to halt the study and offer bortezomib to all dexamethasone-treated study patients.  Time to progression was significantly prolonged in the bortezomib treatment arm (median, 6.2 mo) compared with the dexamethasone arm (median, 3.5 mo; log-rank test, P < 0.0001; hazard ratio, 0.55; 95% confidence interval, 0.44-0.69).  Anal. of overall survival done on the interim database (with 20% of events) showed the superiority of bortezomib for patients (log-rank test, P < 0.05; hazard ratio, 0.57; 95% confidence interval, 0.40-0.81).  Using criteria from the European Group for Blood and Marrow Transplantation, the response rate (complete plus partial response) with bortezomib was also superior to dexamethasone (38% vs. 18%; P < 0.0001).  Adverse events on the bortezomib arm were similar to those previously obsd. in phase 2 studies; some notable adverse events included asthenia, peripheral neuropathy, thrombocytopenia, and neutropenia.  Conclusions: The U.S. FDA had earlier (May 2003) granted bortezomib accelerated approval for the treatment of patients with MM progressing after two prior therapies.  The results of the phase 3 trial and the FDA anal. of the data, along with the sponsor's completion of other postmarketing commitments, confirm bortezomib's benefit and support regular approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprCEo5n3GykbVg90H21EOLACvtfcHk0lgcyjIsmfBWWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xks1Cisb8%253D&md5=943e7a08845337c9813ae01be5de83b3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0170%26sid%3Dliteratum%253Aachs%26aulast%3DKane%26aufirst%3DR.%2BC.%26aulast%3DFarrell%26aufirst%3DR.%2BT.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DUnited%2520States%2520Food%2520and%2520Drug%2520Administration%2520approval%2520summary%253A%2520bortezomib%2520for%2520the%2520treatment%2520of%2520progressive%2520multiple%2520myeloma%2520after%2520one%2520prior%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D2955%26epage%3D2960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Marguet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baggio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagtmann, N.</span><span> </span><span class="NLM_article-title">Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">6874</span><span class="NLM_x">–</span> <span class="NLM_lpage">6879</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=6874-6879&author=D.+Marguetauthor=L.+Baggioauthor=T.+Kobayashiauthor=A.+Bernardauthor=M.+Pierresauthor=P.+F.+Nielsenauthor=U.+Ribelauthor=T.+Watanabeauthor=D.+J.+Druckerauthor=N.+Wagtmann&title=Enhanced+insulin+secretion+and+improved+glucose+tolerance+in+mice+lacking+CD26"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarguet%26aufirst%3DD.%26aulast%3DBaggio%26aufirst%3DL.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DBernard%26aufirst%3DA.%26aulast%3DPierres%26aufirst%3DM.%26aulast%3DNielsen%26aufirst%3DP.%2BF.%26aulast%3DRibel%26aufirst%3DU.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DWagtmann%26aufirst%3DN.%26atitle%3DEnhanced%2520insulin%2520secretion%2520and%2520improved%2520glucose%2520tolerance%2520in%2520mice%2520lacking%2520CD26%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2000%26volume%3D97%26spage%3D6874%26epage%3D6879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm100972f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2011.54.issue-7%3Barticle%3Aarticle%3A10.1021%2Fjm100972f%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm100972f" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799608d7bc82440","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
